

1. http://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S1137-66272015000200012
2. http://www.scielo.org.ar/scielo.php?script=sci_arttext&pid=S0025-76802016000500009
3. <http://www.elsevier.es/es-revista-inmunologia-322-articulo-celulas-dendriticas-ii-utilizacion-clinica-S0213962611000692>
4. <https://www.canceractive.com/cancer-active-page-link.aspx?n=3080>
5. https://www.researchgate.net/publication/7810215_Immunotherapy_Via_Dendritic_Cells
6. <http://medcraveonline.com/IJVV/IJVV-01-00002.pdf>
7. <http://medcraveonline.com/IJVV/IJVV-04-00081.pdf>
8. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3788678/pdf/nihms511491.pdf>
9. <http://www.ias.ac.in/article/fulltext/jbsc/042/01/0161-0173>
10. Kajihara, M., Takakura, K., Kanai, T., Ito, Z., Saito, K., Takami, S., ... Koido, S. (2016). Dendritic cell-based cancer immunotherapy for colorectal cancer. *World Journal of Gastroenterology*, 22(17), 4275–4286. <http://doi.org/10.3748/wjg.v22.i17.4275>
11. Safety and preliminary evidence of biologic efficacy of a mammaglobin-a DNA vaccine in patients with stable metastatic breast cancer. Tiriveedhi V et al. *Clin Cancer Res*. 2014 Dec 1;20(23):5964-75.
12. Granulocyte macrophage colony-stimulating factor--secreting allogeneic cellular immunotherapy for hormone- refractory prostate cancer. Small EJ et al. *Clin Cancer Res*. 2007 Jul 1;13(13):3883-91.
13. Increased anti-tumor immunity that correlates with clinical benefit and induction of neoantigens reactivity following autologous tumor lysate-pulsed dendritic cells vaccination in recurrent ovarian cancer- Ophir E, Bobisse, S, Kandalaf L.E., Tanyi J., Genolet, R, Zsiros E, Torigian D, Mick, R, Harrari A and Coukos G. *CIMT May 2015*
14. Autologous oxidized whole-tumor antigen vaccine in combination with angiogenesis blockade elicits antitumor immune response in ovarian cancer- Tanyi J., Kandalaf L.E., Ophir E, Bobisse, Genolet, R, Zsiros E, Torigian D, Mick, R, Harrari A and Coukos G. *ASCO June 2015*
15. Adjuvant active specific immunotherapy for human colorectal cancer: 6.5- year median follow-up of a phase III prospectively randomized trial. Hoover HC Jr et al. (1993) *J Clin Oncol* 11:390–399
16. Adjuvant active specific immunotherapy of stage II and stage III colon cancer with an autologous tumor cell vaccine: first randomized phase III trials show promise. Hanna MG, et al. *Vaccine*. 2001;19:2576–2582
17. Phase I trial of a multi-epitope-pulsed dendritic cell vaccine for patients with newly diagnosed glioblastoma. Phuphanich S et al. *Cancer Immunol Immunother*. 2013 Jan;62(1):125-35. doi: 10.1007/s00262-012-1319-0. Epub 2012 Jul 31.
18. Survival with AGS-003, an autologous dendritic cell-based immunotherapy, in combination with sunitinib in unfavorable risk patients with advanced renal cell carcinoma (RCC): Phase 2 study results. Amin A et al. *J Immunother Cancer*. 2015 Apr 21;3:14. doi: 10.1186/s40425-015-0055-3. eCollection 2015.
19. A phase II study of active specific immunotherapy and 5-FU/Leucovorin as adjuvant therapy for stage III colon carcinoma. A Baars et al. *Br J Cancer*. 2002 April 22; 86(8): 1230–1234.
20. Phase II randomized controlled trial of an epidermal growth factor vaccine in advanced non-small-cell lung cancer. Neningen Vinageras, E. et al. *J. Clin. Oncol*. 26, 1452–1458 (2008).

21. Immunotherapy of hepatocellular carcinoma: Unique challenges and clinical opportunities. Angela D. Pardee, Lisa H. Butterfield. *Oncoimmunology*. 2012 Jan 1; 1(1): 48–55. doi: 10.4161/onci.1.1.18344
22. Dendritic cell vaccines: A review of recent developments and their potential pediatric application. Hum Vaccin Immunother. 2016 Sep; 12(9): 2232–2239. Cancer testis antigen and immunotherapy. Immunotargets Ther. 2013; 2: 11–19.
23. Cellular immunotherapy for pediatric solid tumors. *Cytotherapy*. 2015 Jan; 17(1): 3–17.
24. Intratumoral Immunization: A New Paradigm for Cancer Therapy. *Clin Cancer Res.* 2014 Apr 1; 20(7): 1747–1756.
25. Complete Remission Following Decitabine/Dendritic Cell Vaccine for Relapsed Neuroblastoma. *Pediatrics* (2013;131[1]:e336–e341.
26. Immunotherapy advances in uro-genital malignancies. *Critical Reviews in Oncology/Hematology* 105 (2016) 52–64
27. Draube, A., Klein-González, N., Mattheus, S., Brilliant, C., Hellmich, M., Engert, A., & von Bergwelt-Baildon, M. (2011). Dendritic cell based tumor vaccination in prostate and renal cell cancer: a systematic review and meta-analysis. *PLoS one*, 6(4), e18801.
28. Berntsen, A., Geertsen, P. F., & Svane, I. M. (2006). Therapeutic dendritic cell vaccination of patients with renal cell carcinoma. *European urology*, 50(1), 34-43.
29. Emerging immunotherapies for renal cell carcinoma. *Ann. Escudier, B.*, 2012. *Oncol.* 23, 35–40.
30. Hawiger, D., Inaba, K., Dorsett, Y., Guo, M., Mahnke, K., Rivera, M., et al., 2001. Dendritic cells induce peripheral T cell unresponsiveness under steady state conditions in vivo. *J. Exp. Med.* 194, 769–779.
31. Noessner, E., Brech, D., Mandler, A., Masouris, I., Schlenker, R., Prinz, P., 2012. Intratumoral alterations of dendritic-cell differentiation and CD8(+) T-cell anergy are immune escape mechanisms of clear cell renal cell carcinoma. *Oncoimmunology* 1, 1451–1453.
32. Genetic immunotherapy for cancer. Oncologist. 2000;5(2):87-98.
33. Immunotherapy of Autologous Tumor Lysate-loaded Dendritic Cell Vaccines by a Closed-flow Electroporation System for Solid Tumors . *ANTICANCER RESEARCH* 33: 2971-2976 (2013)
34. Autologous Tumor Lysate-pulsed Dendritic Cell Immunotherapy for Pediatric Patients with Newly Diagnosed or Recurrent High- grade Gliomas *Anticancer Res.* 2013 May; 33(5): 2047–2056.
35. Clinical Development in Dendritic Cell Based Immunotherapy *Journal of Stem Cell Research & Therapeutics*. Volume 1 Issue 2 - 2016
36. Successful immunological treatment of gallbladder cancer in India. *J Zhejiang Univ SCIENCE B* 2006 7(9):719-724
37. Cancer immunotherapy via dendritic cells. *NATURE REVIEWS. VOLUME 12 | APRIL 2012*, 265-277
38. Dendritic Cell Immunotherapy for the Treatment of Neoplastic Disease. *Biology of Blood and Marrow Transplantation* 12:113-125 (2006)
39. GAO, Daiqing, et al. Autologous tumor lysate-pulsed dendritic cell immunotherapy with cytokine-induced killer cells improves survival in gastric and colorectal cancer patients. *PLoS one*, 2014, vol. 9, no 4, p. e93886.
40. Hoffmann, J. M., Schmitt, M., Ni, M., & Schmitt, A. (2017). Next-generation dendritic cell-based vaccines for leukemia patients.

41. Anguille, S., Van Tendeloo, V., & Berneman, Z. (2012). Dendritic cell-based therapeutic vaccination for acute myeloid leukemia. *Bulletin du cancer*, 99(6), 635-642.
42. VAN DE VELDE, A. L., Berneman, Z. N., & VAN TENDELOO, V. F. (2008). L'immunothérapie des cancers hématologiques par les cellules dendritiques. *Bulletin du cancer*, 95(3), 320-326.
43. Schott, M., Seissler, J., Lettmann, M., Fouxon, V., Scherbaum, W. A., & Feldkamp, J. (2001). Immunotherapy for medullary thyroid carcinoma by dendritic cell vaccination. *The Journal of Clinical Endocrinology & Metabolism*, 86(10), 4965-4969.
44. Palucka, K., & Banchereau, J. (2012). Cancer immunotherapy via dendritic cells. *Nature Reviews Cancer*, 12(4), 265-277.
45. Hirschowitz, E. A., Foody, T., Kryscio, R., Dickson, L., Sturgill, J., & Yannelli, J. (2004). Autologous dendritic cell vaccines for non-small-cell lung cancer. *Journal of Clinical Oncology*, 22(14), 2808-2815.
46. Nestle, F. O., Aljagic, S., Gilliet, M., Sun, Y., Grabbe, S., Dummer, R., ... & Schadendorf, D. (1998). Vaccination of melanoma patients with peptide-or tumorlysate-pulsed dendritic cells. *Nature medicine*, 4(3), 328-332.
47. Okamoto M, Kobayashi M, Yonemitsu Y, Koido S, Homma S. Dendritic cell-based vaccine for pancreatic cancer in Japan. *World Journal of Gastrointestinal Pharmacology and Therapeutics*. 2016;7(1):133-138. doi:10.4292/wjgpt.v7.i1.133.
48. Mulé, J. J. (2009). Dendritic Cell-Based Vaccines for Pancreatic Cancer and Melanoma. *Annals of the New York Academy of Sciences*, 1174(1), 33-40.
49. Burgdorf, S. K. (2010). Dendritic cell vaccination of patients with metastatic colorectal cancer. *Dan Med Bull*, 57(9), B4171.
50. Dendritic Cell Immunotherapy for the Treatment of Neoplastic Disease. Decker, William K. et al. *Biology of Blood and Marrow Transplantation*, Volume 12, Issue 2, 113 – 125
51. DNJ Hart¹ and GR Hill¹. Dendritic cell immunotherapy for cancer: Application to low-grade lymphoma and multiple mieloma; *Immunology and Cell Biology* (1999) 77, 451–459; doi:10.1046/j.1440-1711.1999.00859.x
52. Immunotherapy. 2010 Jan 1; 2(1): 57. Personalized dendritic cell-based tumor immunotherapy. Nona Janikashvili¹, Nicolas Larmonier^{1,2} and Emmanuel Katsanis^{1,2,3,+}
53. LOPEZ, Mercedes et al. Avances en inmunoterapia celular contra el melanoma maligno. *Rev. méd. Chile* [online]. 2004, vol.132, n.9 [citado 2017-06-06], pp.1115-1126.
54. GATO, M. et al. Inmunoterapia genética con células dendríticas para el tratamiento del cáncer. *Anales Sis San Navarra* [online]. 2015, vol.38, n.2 [citado 2017-06-06], pp.279-287
55. Lancet Oncol. 2014 Jun;15(7):e257-67. doi: 10.1016/S1470-2045(13)70585-0. Clinical use of dendritic cells for cancer therapy. Anguille S¹, Smits EL², Lion E³, van Tendeloo VF³, Berneman ZN⁴.
56. Immunity. 2013 Jul 25;39(1):38-48. doi: 10.1016/j.immuni.2013.07.004..Dendritic-cell-based therapeutic cancer vaccines. Palucka K¹, Banchereau J.
57. ARANGO PRADO, María del C. y GONZALEZ SANCHEZ, Alicia. Vacunas terapéuticas en cáncer: Ensayos clínicos actuales. *Rev cubana med* [online]. 2002, vol.41, n.6 [citado 2017-06-06], pp. 0-0 .
58. BERMUDEZ-MORALES, Víctor Hugo; PERALTA-ZARAGOZA, Oscar y MADRID-MARINA, Vicente. Terapia génica con citocinas contra cáncer cervicouterino. *Salud pública Méx* [online]. 2005, vol.47, n.6 [citado 2017-06-06], pp.458-468.
59. Droppelmann M, Nicolás Et Al. Nuevas Terapias Sistémicas Para El Tratamiento Del Melanoma. *Rev Chil Cir* [Online]. 2016, Vol.68, N.1 [Citado 2017-06-06], Pp.81-86.

60. Bull Cancer. 2012 Jun;99(6):635-42. Dendritic cell-based therapeutic vaccination for acute myeloid leukemia. Anguille S¹, Van Tendeloo V, Berneman Z.
61. Teilo H. Schaller & John H. Sampson (2016): Advances and challenges: dendritic cell vaccination strategies for glioblastoma, Expert Review of Vaccines, DOI: 10.1080/14760584.2016.1218762
62. INOGES, S. et al. Inmunoterapia activa en el tratamiento de neoplasias hematológicas. *Anales Sis San Navarra* [online]. 2004, vol.27, n.1 [citado 2017-06-06], pp.45-62.
63. Mature autologous dendritic cell vaccines in advanced non-small cell lung cancer: a phase I pilot study. Perroud MW Jr et al. J Exp Clin Cancer Res. (2011)
64. Autologous dendritic cell vaccines for non-small-cell lung cancer. Hirschowitz EA et al. J Clin Oncol. (2004)
65. Molecular and clinical oncology 4: 129-133, 2016. Clinical outcome of immunotherapy with dendritic cell vaccine and cytokine-induced killer cell therapy in hepatobiliary and pancreatic cancer. Lihong zhang¹, wei zhu², jiali li³, xuejing yang³, yanjie ren³, jingxiu niu³ and yan pang³
66. Brenner H, Kloor M, Pox CP. Colorectal cancer. Lancet. 2014;383:1490–1502. [PubMed]
67. Kerr D. Clinical development of gene therapy for colorectal cancer. Nat Rev Cancer. 2003;3:615–622. [PubMed]
68. Koido S, Ohkusa T, Homma S, Namiki Y, Takakura K, Saito K, Ito Z, Kobayashi H, Kajihara M, Uchiyama K, et al. Immunotherapy for colorectal cancer. World J Gastroenterol. 2013;19:8531–8542. [PMC free article][PubMed]
69. Koido S, Hara E, Homma S, Torii A, Toyama Y, Kawahara H, Watanabe M, Yanaga K, Fujise K, Tajiri H, et al. Dendritic cells fused with allogeneic colorectal cancer cell line present multiple colorectal cancer-specific antigens and induce antitumor immunity against autologous tumor cells. Clin Cancer Res. 2005;11:7891–7900. [PubMed]
70. Zhu MZ, Marshall J, Cole D, Schlom J, Tsang KY. Specific cytolytic T-cell responses to human CEA from patients immunized with recombinant avipox-CEA vaccine. Clin Cancer Res. 2000;6:24–33. [PubMed]
71. Berinstein NL. Carcinoembryonic antigen as a target for therapeutic anticancer vaccines: a review. J Clin Oncol. 2002;20:2197–2207. [PubMed]
72. Oji Y, Ogawa H, Tamaki H, Oka Y, Tsuboi A, Kim EH, Soma T, Tatekawa T, Kawakami M, Asada M, et al. Expression of the Wilms' tumor gene WT1 in solid tumors and its involvement in tumor cell growth. Jpn J Cancer Res. 1999;90:194–204. [PubMed]
73. Shimodaira S, Sano K, Hirabayashi K, Koya T, Higuchi Y, Mizuno Y, Yamaoka N, Yuzawa M, Kobayashi T, Ito K, et al. Dendritic Cell-Based Adjuvant Vaccination Targeting Wilms' Tumor 1 in Patients with Advanced Colorectal Cancer. Vaccines (Basel) 2015;3:1004–1018. [PMC free article][PubMed]
74. Ajioka Y, Allison LJ, Jass JR. Significance of MUC1 and MUC2 mucin expression in colorectal cancer. J Clin Pathol. 1996;49:560–564. [PMC free article] [PubMed]
75. Mashino K, Sadanaga N, Tanaka F, Yamaguchi H, Nagashima H, Inoue H, Sugimachi K, Mori M. Expression of multiple cancer-testis antigen genes in gastrointestinal and breast carcinomas. Br J Cancer. 2001;85:713–720. [PMC free article] [PubMed]

76. Li M, Yuan YH, Han Y, Liu YX, Yan L, Wang Y, Gu J. Expression profile of cancer-testis genes in 121 human colorectal cancer tissue and adjacent normal tissue. *Clin Cancer Res.* 2005;11:1809–1814. [PubMed]
77. Sang M, Lian Y, Zhou X, Shan B. MAGE-A family: attractive targets for cancer immunotherapy. *Vaccine.* 2011;29:8496–8500. [PubMed]
78. Speetjens FM, Kuppen PJ, Welters MJ, Essahsah F, Voet van den Brink AM, Lantrua MG, Valentijn AR, Oostendorp J, Fathers LM, Nijman HW, et al. Induction of p53-specific immunity by a p53 synthetic long peptide vaccine in patients treated for metastatic colorectal cancer. *Clin Cancer Res.* 2009;15:1086–1095. [PubMed]
79. Grizzi F, Bianchi P, Malesci A, Laghi L. Prognostic value of innate and adaptive immunity in colorectal cancer. *World J Gastroenterol.* 2013;19:174–184. [PMC free article] [PubMed]
80. Ahmed D, Eide PW, Eilertsen IA, Danielsen SA, Eknæs M, Hektoen M, Lind GE, Lothe RA. Epigenetic and genetic features of 24 colon cancer cell lines. *Oncogenesis.* 2013;2:e71. [PMC free article] [PubMed]
81. Takahara A, Koido S, Ito M, Nagasaki E, Sagawa Y, Iwamoto T, Komita H, Ochi T, Fujiwara H, Yasukawa M, et al. Gemcitabine enhances Wilms' tumor gene WT1 expression and sensitizes human pancreatic cancer cells with WT1-specific T-cell-mediated antitumor immune response. *Cancer Immunol Immunother.* 2011;60:1289–1297. [PubMed]
82. Koido S, Homma S, Takahara A, Namiki Y, Komita H, Uchiyama K, Ito M, Gong J, Ohkusa T, Tajiri H. Immunotherapy synergizes with chemotherapy targeting pancreatic cancer. *Immunotherapy.* 2012;4:5–7. [PubMed]
83. Al-Ejeh F, Darby JM, Brown MP. Chemotherapy synergizes with radioimmunotherapy targeting La autoantigen in tumors. *PLoS One.* 2009;4:e4630. [PMC free article] [PubMed]
84. Boon T, Coulie PG, Van den Eynde B. Tumor antigens recognized by T cells. *Immunol Today.* 1997;18:267–268. [PubMed]
85. Steinman RM, Swanson J. The endocytic activity of dendritic cells. *J Exp Med.* 1995;182:283–288. [PMC free article] [PubMed]
86. Tanaka Y, Koido S, Ohana M, Liu C, Gong J. Induction of impaired antitumor immunity by fusion of MHC class II-deficient dendritic cells with tumor cells. *J Immunol.* 2005;174:1274–1280. [PubMed]
87. Adam C, King S, Allgeier T, Braumüller H, Lüking C, Mysliwietz J, Kriegeskorte A, Busch DH, Röcken M, Mocikat R. DC-NK cell cross talk as a novel CD4+ T-cell-independent pathway for antitumor CTL induction. *Blood.* 2005;106:338–344. [PubMed]
88. van Beek JJ, Wimmers F, Hato SV, de Vries IJ, Sköld AE. Dendritic cell cross talk with innate and innate-like effector cells in antitumor immunity: implications for DC vaccination. *Crit Rev Immunol.* 2014;34:517–536. [PubMed]
89. Wehner R, Dietze K, Bachmann M, Schmitz M. The bidirectional crosstalk between human dendritic cells and natural killer cells. *J Innate Immun.* 2011;3:258–263. [PubMed]
90. Steinman RM, Banchereau J. Taking dendritic cells into medicine. *Nature.* 2007;449:419–426. [PubMed]
91. Nestle FO, Alijagic S, Gilliet M, Sun Y, Grabbe S, Dummer R, Burg G, Schadendorf D. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. *Nat Med.* 1998;4:328–332. [PubMed]
92. Koido S, Homma S, Okamoto M, Takakura K, Mori M, Yoshizaki S, Tsukinaga S, Odahara S, Koyama S, Imazu H, et al. Treatment with chemotherapy and dendritic cells pulsed with multiple Wilms' tumor 1 (WT1)-specific MHC class I/II-restricted epitopes for pancreatic cancer. *Clin Cancer Res.* 2014;20:4228–4239. [PubMed]

93. Kimura Y, Tsukada J, Tomoda T, Takahashi H, Imai K, Shimamura K, Sunamura M, Yonemitsu Y, Shimodaira S, Koido S, et al. Clinical and immunologic evaluation of dendritic cell-based immunotherapy in combination with gemcitabine and/or S-1 in patients with advanced pancreatic carcinoma. *Pancreas*. 2012;41:195–205. [PubMed]
94. Gilboa E, Vieweg J. Cancer immunotherapy with mRNA-transfected dendritic cells. *Immunol Rev*. 2004;199:251–263. [PubMed]
95. Mackensen A, Herbst B, Chen JL, Köhler G, Noppen C, Herr W, Spagnoli GC, Cerundolo V, Lindemann A. Phase I study in melanoma patients of a vaccine with peptide-pulsed dendritic cells generated in vitro from CD34(+) hematopoietic progenitor cells. *Int J Cancer*. 2000;86:385–392. [PubMed]
96. Palucka K, Ueno H, Banchereau J. Recent developments in cancer vaccines. *J Immunol*. 2011;186:1325–1331. [PMC free article] [PubMed]
97. Gong J, Chen D, Kashiwaba M, Kufe D. Induction of antitumor activity by immunization with fusions of dendritic and carcinoma cells. *Nat Med*. 1997;3:558–561. [PubMed]
98. Gong J, Koido S, Calderwood SK. Cell fusion: from hybridoma to dendritic cell-based vaccine. *Expert Rev Vaccines*. 2008;7:1055–1068.[PubMed]
99. Cavallo F, Curcio C, Forni G. Immunotherapy and immunoprevention of cancer: where do we stand? *Expert Opin Biol Ther*. 2005;5:717–726.[PubMed]
100. Giorda E, Sibilio L, Martayan A, Moretti S, Ventura I, Mottolese M, Ferrara GB, Cappellacci S, Eibenschutz L, Catricalà C, et al. The antigen processing machinery of class I human leukocyte antigens: linked patterns of gene expression in neoplastic cells. *Cancer Res*. 2003;63:4119–4127.[PubMed]
101. Koido S, Homma S, Takahara A, Namiki Y, Tsukinaga S, Mitobe J, Odahara S, Yukawa T, Matsudaira H, Nagatsuma K, et al. Current immunotherapeutic approaches in pancreatic cancer. *Clin Dev Immunol*. 2011;2011:267539. [PMC free article] [PubMed]
102. Koido S, Homma S, Hara E, Namiki Y, Takahara A, Komita H, Nagasaki E, Ito M, Ohkusa T, Gong J, et al. Regulation of tumor immunity by tumor/dendritic cell fusions. *Clin Dev Immunol*. 2010;2010:516768.[PMC free article] [PubMed]
103. Adachi K, Tamada K. Immune checkpoint blockade opens an avenue of cancer immunotherapy with a potent clinical efficacy. *Cancer Sci*. 2015;106:945–950. [PMC free article] [PubMed]
104. Droeser RA, Hirt C, Viehl CT, Frey DM, Nebiker C, Huber X, Zlobec I, Eppenberger-Castori S, Tzankov A, Rosso R, et al. Clinical impact of programmed cell death ligand 1 expression in colorectal cancer. *Eur J Cancer*. 2013;49:2233–2242. [PubMed]
105. Anitei MG, Zeitoun G, Mlecnik B, Marliot F, Haicheur N, Tosi AM, Kirilovsky A, Lagorce C, Bindea G, Ferrari D, et al. Prognostic and predictive values of the immunoscore in patients with rectal cancer. *Clin Cancer Res*. 2014;20:1891–1899. [PubMed]
106. Merika E, Saif MW, Katz A, Syrigos K, Morse M. Review. Colon cancer vaccines: an update. *In Vivo*. 2010;24:607–628. [PubMed]
107. Quigley DA, Kristensen V. Predicting prognosis and therapeutic response from interactions between lymphocytes and tumor cells. *Mol Oncol*. 2015;9:2054–2062. [PubMed]
108. Shi SJ, Wang LJ, Wang GD, Guo ZY, Wei M, Meng YL, Yang AG, Wen WH. B7-H1 expression is associated with poor prognosis in colorectal carcinoma and regulates the proliferation and invasion of HCT116 colorectal cancer cells. *PLoS One*. 2013;8:e76012. [PMC free article] [PubMed]

109. Wu P, Wu D, Li L, Chai Y, Huang J. PD-L1 and Survival in Solid Tumors: A Meta-Analysis. *PLoS One*. 2015;10:e0131403.[PMC free article] [PubMed]
110. Zhao LW, Li C, Zhang RL, Xue HG, Zhang FX, Zhang F, Gai XD. B7-H1 and B7-H4 expression in colorectal carcinoma: correlation with tumor FOXP3(+) regulatory T-cell infiltration. *Acta Histochem*. 2014;116:1163–1168. [PubMed]
111. Morse MA, Deng Y, Coleman D, Hull S, Kitrell-Fisher E, Nair S, Schlom J, Ryback ME, Lyerly HK. A Phase I study of active immunotherapy with carcinoembryonic antigen peptide (CAP-1)-pulsed, autologous human cultured dendritic cells in patients with metastatic malignancies expressing carcinoembryonic antigen. *Clin Cancer Res*. 1999;5:1331–1338. [PubMed]
112. Morse MA, Nair SK, Mosca PJ, Hobeika AC, Clay TM, Deng Y, Boczkowski D, Proia A, Neidzwiecki D, Clavien PA, et al. Immunotherapy with autologous, human dendritic cells transfected with carcinoembryonic antigen mRNA. *Cancer Invest*. 2003;21:341–349. [PubMed]
113. Morse MA, Clay TM, Hobeika AC, Osada T, Khan S, Chui S, Niedzwiecki D, Panicali D, Schlom J, Lyerly HK. Phase I study of immunization with dendritic cells modified with fowlpox encoding carcinoembryonic antigen and costimulatory molecules. *Clin Cancer Res*. 2005;11:3017–3024. [PubMed]
114. Osada T, Clay T, Hobeika A, Lyerly HK, Morse MA. NK cell activation by dendritic cell vaccine: a mechanism of action for clinical activity. *Cancer Immunol Immunother*. 2006;55:1122–1131. [PubMed]
115. Lion E, Smits EL, Berneman ZN, Van Tendeloo VF. NK cells: key to success of DC-based cancer vaccines? *Oncologist*. 2012;17:1256–1270.[PMC free article] [PubMed]
116. Sakakibara M, Kanto T, Hayakawa M, Kuroda S, Miyatake H, Itose I, Miyazaki M, Kakita N, Higashitani K, Matsubara T, et al. Comprehensive immunological analyses of colorectal cancer patients in the phase I/II study of quickly matured dendritic cell vaccine pulsed with carcinoembryonic antigen peptide. *Cancer Immunol Immunother*. 2011;60:1565–1575.[PubMed]
117. Fong L, Hou Y, Rivas A, Benike C, Yuen A, Fisher GA, Davis MM, Engleman EG. Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy. *Proc Natl Acad Sci USA*. 2001;98:8809–8814. [PMC free article] [PubMed]
118. Itoh T, Ueda
119. Y, Kawashima I, Nukaya I, Fujiwara H, Fuji N, Yamashita T, Yoshimura T, Okugawa K, Iwasaki T, et al. Immunotherapy of solid cancer using dendritic cells pulsed with the HLA-A24-restricted peptide of carcinoembryonic antigen. *Cancer Immunol Immunother*. 2002;51:99–106.[PubMed]
120. Liu KJ, Wang CC, Chen LT, Cheng AL, Lin DT, Wu YC, Yu WL, Hung YM, Yang HY, Juang SH, et al. Generation of carcinoembryonic antigen (CEA)-specific T-cell responses in HLA-A*0201 and HLA-A*2402 late-stage colorectal cancer patients after vaccination with dendritic cells loaded with CEA peptides. *Clin Cancer Res*. 2004;10:2645–2651. [PubMed]
121. Matsuda K, Tsunoda T, Tanaka H, Umamo Y, Tanimura H, Nukaya I, Takesako K, Yamaue H. Enhancement of cytotoxic T-lymphocyte responses in patients with gastrointestinal malignancies following vaccination with CEA peptide-pulsed dendritic cells. *Cancer Immunol Immunother*. 2004;53:609–616. [PubMed]
122. Ueda Y, Itoh T, Nukaya I, Kawashima I, Okugawa K, Yano Y, Yamamoto Y, Naitoh K, Shimizu K, Imura K, et al. Dendritic cell-based immunotherapy of cancer with carcinoembryonic antigen-derived, HLA-A24-restricted CTL epitope: Clinical outcomes of 18

- patients with metastatic gastrointestinal or lung adenocarcinomas. *Int J Oncol.* 2004;24:909–917. [PubMed]
123. Lesterhuis WJ, de Vries IJ, Schuurhuis DH, Boullart AC, Jacobs JF, de Boer AJ, Scharenborg NM, Brouwer HM, van de Rakt MW, Figdor CG, et al. Vaccination of colorectal cancer patients with CEA-loaded dendritic cells: antigen-specific T cell responses in DTH skin tests. *Ann Oncol.* 2006;17:974–980. [PubMed]
 124. Babatz J, Röllig C, Löbel B, Folprecht G, Haack M, Günther H, Köhne CH, Ehniger G, Schmitz M, Bornhäuser M. Induction of cellular immune responses against carcinoembryonic antigen in patients with metastatic tumors after vaccination with altered peptide ligand-loaded dendritic cells. *Cancer Immunol Immunother.* 2006;55:268–276. [PubMed]
 125. Oji Y, Yamamoto H, Nomura M, Nakano Y, Ikeba A, Nakatsuka S, Abeno S, Kiyotoh E, Jomgeow T, Sekimoto M, et al. Overexpression of the Wilms' tumor gene WT1 in colorectal adenocarcinoma. *Cancer Sci.* 2003;94:712–717. [PubMed]
 126. Miyata Y, Kumagai K, Nagaoka T, Kitaura K, Kaneda G, Kanazawa H, Suzuki S, Hamada Y, Suzuki R. Clinicopathological significance and prognostic value of Wilms' tumor gene expression in colorectal cancer. *Cancer Biomark.* 2015;15:789–797. [PubMed]
 127. Cheever MA, Allison JP, Ferris AS, Finn OJ, Hastings BM, Hecht TT, Mellman I, Prindiville SA, Viner JL, Weiner LM, et al. The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. *Clin Cancer Res.* 2009;15:5323–5337. [PubMed]
 128. Oka Y, Sugiyama H. WT1 peptide vaccine, one of the most promising cancer vaccines: its present status and the future prospects. *Immunotherapy.* 2010;2:591–594. [PubMed]
 129. Sugiyama H. WT1 (Wilms' tumor gene 1): biology and cancer immunotherapy. *Jpn J Clin Oncol.* 2010;40:377–387. [PubMed]
 130. Chemoimmunotherapy targeting Wilms' tumor 1 (WT1)-specific cytotoxic T lymphocyte and helper T cell responses for patients with pancreatic cancer. *Oncoimmunology.* 2014;3:e958950. [PMC free article][PubMed]
 131. Sadanaga N, Nagashima H, Mashino K, Tahara K, Yamaguchi H, Ohta M, Fujie T, Tanaka F, Inoue H, Takesako K, et al. Dendritic cell vaccination with MAGE peptide is a novel therapeutic approach for gastrointestinal carcinomas. *Clin Cancer Res.* 2001;7:2277–2284. [PubMed]
 132. Tanaka F, Haraguchi N, Isikawa K, Inoue H, Mori M. Potential role of dendritic cell vaccination with MAGE peptides in gastrointestinal carcinomas. *Oncol Rep.* 2008;20:1111–1116. [PubMed]
 133. Morse MA, Niedzwiecki D, Marshall JL, Garrett C, Chang DZ, Aklilu M, Crocenzi TS, Cole DJ, Dessureault S, Hobeika AC, et al. A randomized phase II study of immunization with dendritic cells modified with poxvectors encoding CEA and MUC1 compared with the same poxvectors plus GM-CSF for resected metastatic colorectal cancer. *Ann Surg.* 2013;258:879–886. [PMC free article] [PubMed]
 134. Mohebtash M, Tsang KY, Madan RA, Huen NY, Poole DJ, Jochems C, Jones J, Ferrara T, Heery CR, Arlen PM, et al. A pilot study of MUC-1/CEA/TRICOM poxviral-based vaccine in patients with metastatic breast and ovarian cancer. *Clin Cancer Res.* 2011;17:7164–7173. [PMC free article] [PubMed]
 135. Brossart P, Stuhler G, Flad T, Stevanovic S, Rammensee HG, Kanz L, Brugger W. Her-2/neu-derived peptides are tumor-associated antigens expressed by human renal cell and

- colon carcinoma lines and are recognized by in vitro induced specific cytotoxic T lymphocytes. *Cancer Res.* 1998;58:732–736. [PubMed]
136. Kavanagh B, Ko A, Venook A, Margolin K, Zeh H, Lotze M, Schillinger B, Liu W, Lu Y, Mitsky P, et al. Vaccination of metastatic colorectal cancer patients with matured dendritic cells loaded with multiple major histocompatibility complex class I peptides. *J Immunother.* 2007;30:762–772. [PubMed]
 137. Brossart P, Heinrich KS, Stuhler G, Behnke L, Reichardt VL, Stevanovic S, Muhm A, Rammensee HG, Kanz L, Brugger W. Identification of HLA-A2-restricted T-cell epitopes derived from the MUC1 tumor antigen for broadly applicable vaccine therapies. *Blood.* 1999;93:4309–4317. [PubMed]
 138. de Gruijl TD, van den Eertwegh AJ, Pinedo HM, Scheper RJ. Whole-cell cancer vaccination: from autologous to allogeneic tumor- and dendritic cell-based vaccines. *Cancer Immunol Immunother.* 2008;57:1569–1577.[PMC free article] [PubMed]
 139. Koido S, Kashiwaba M, Chen D, Gendler S, Kufe D, Gong J. Induction of antitumor immunity by vaccination of dendritic cells transfected with MUC1 RNA. *J Immunol.* 2000;165:5713–5719. [PubMed]
 140. Nair SK, Hull S, Coleman D, Gilboa E, Lysterly HK, Morse MA. Induction of carcinoembryonic antigen (CEA)-specific cytotoxic T-lymphocyte responses in vitro using autologous dendritic cells loaded with CEA peptide or CEA RNA in patients with metastatic malignancies expressing CEA. *Int J Cancer.* 1999;82:121–124. [PubMed]
 141. Rains N, Cannan RJ, Chen W, Stubbs RS. Development of a dendritic cell (DC)-based vaccine for patients with advanced colorectal cancer. *Hepatogastroenterology.* 2001;48:347–351. [PubMed]
 142. Kajihara M, Takakura K, Ohkusa T, Koido S. The impact of dendritic cell-tumor fusion cells on cancer vaccines - past progress and future strategies. *Immunotherapy.* 2015;7:1111–1122. [PubMed]
 143. Galea-Lauri J, Darling D, Mufti G, Harrison P, Farzaneh F. Eliciting cytotoxic T lymphocytes against acute myeloid leukemia-derived antigens: evaluation of dendritic cell-leukemia cell hybrids and other antigen-loading strategies for dendritic cell-based vaccination. *Cancer Immunol Immunother.* 2002;51:299–310. [PubMed]
 144. Homma S, Kikuchi T, Ishiji N, Ochiai K, Takeyama H, Saotome H, Sagawa Y, Hara E, Kufe D, Ryan JL, et al. Cancer immunotherapy by fusions of dendritic and tumour cells and rh-IL-12. *Eur J Clin Invest.* 2005;35:279–286. [PubMed]
 145. Homma S, Sagawa Y, Ito M, Ohno T, Toda G. Cancer immunotherapy using dendritic/tumour-fusion vaccine induces elevation of serum anti-nuclear antibody with better clinical responses. *Clin Exp Immunol.* 2006;144:41–47. [PMC free article] [PubMed]
 146. Fields RC, Shimizu K, Mulé JJ. Murine dendritic cells pulsed with whole tumor lysates mediate potent antitumor immune responses in vitro and in vivo. *Proc Natl Acad Sci USA.* 1998;95:9482–9487.[PMC free article] [PubMed]
 147. Koido S, Homma S, Okamoto M, Namiki Y, Takakura K, Uchiyama K, Kajihara M, Arihiro S, Imazu H, Arakawa H, et al. Fusions between dendritic cells and whole tumor cells as anticancer vaccines. *Oncoimmunology.* 2013;2:e24437. [PMC free article] [PubMed]
 148. Tamir A, Basagila E, Kagahzian A, Jiao L, Jensen S, Nicholls J, Tate P, Stamp G, Farzaneh F, Harrison P, et al. Induction of tumor-specific T-cell responses by vaccination with tumor lysate-loaded dendritic cells in colorectal cancer patients with carcinoembryonic-antigen positive tumors. *Cancer Immunol Immunother.* 2007;56:2003–2016. [PubMed]

149. Toh HC, Wang WW, Chia WK, Kvistborg P, Sun L, Teo K, Phoon YP, Soe Y, Tan SH, Hee SW, et al. Clinical Benefit of Allogeneic Melanoma Cell Lysate-Pulsed Autologous Dendritic Cell Vaccine in MAGE-Positive Colorectal Cancer Patients. *Clin Cancer Res.* 2009;15:7726–7736. [PubMed]
150. Parsons R, Li GM, Longley MJ, Fang WH, Papadopoulos N, Jen J, de la Chapelle A, Kinzler KW, Vogelstein B, Modrich P. Hypermutability and mismatch repair deficiency in RER+ tumor cells. *Cell.* 1993;75:1227–1236.[PubMed]
151. Timmermann B, Kerick M, Roehr C, Fischer A, Isau M, Boerno ST, Wunderlich A, Barmeyer C, Seemann P, Koenig J, et al. Somatic mutation profiles of MSI and MSS colorectal cancer identified by whole exome next generation sequencing and bioinformatics analysis. *PLoS One.* 2010;5:e15661. [PMC free article] [PubMed]
152. Aguiar PN, Tadokoro H, Forones NM, de Mello RA. MMR deficiency may lead to a high immunogenicity and then an improvement in anti-PD-1 efficacy for metastatic colorectal cancer. *Immunotherapy.* 2015;7:1133–1134. [PubMed]
153. Aaltonen LA, Peltomäki P, Leach FS, Sistonen P, Pylkkänen L, Mecklin JP, Järvinen H, Powell SM, Jen J, Hamilton SR. Clues to the pathogenesis of familial colorectal cancer. *Science.* 1993;260:812–816. [PubMed]
154. Hampel H, Frankel WL, Martin E, Arnold M, Khanduja K, Kuebler P, Nakagawa H, Sotamaa K, Prior TW, Westman J, et al. Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer) *N Engl J Med.* 2005;352:1851–1860. [PubMed]
155. Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, Skora AD, Luber BS, Azad NS, Laheru D, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. *N Engl J Med.* 2015;372:2509–2520.[PMC free article] [PubMed]
156. Lee V, Le DT. Efficacy of PD-1 blockade in tumors with MMR deficiency. *Immunotherapy.* 2016;8:1–3. [PubMed]
157. Yu P, Steel JC, Zhang M, Morris JC, Waldmann TA. Simultaneous blockade of multiple immune system inhibitory checkpoints enhances antitumor activity mediated by interleukin-15 in a murine metastatic colon carcinoma model. *Clin Cancer Res.* 2010;16:6019–6028. [PMC free article][PubMed]
158. Mukherji B, Chakraborty NG, Yamasaki S, et al. Induction of antigen-specific cytolytic T cells *in situ* in human melanoma by immunization with synthetic peptide-pulsed autologous antigen presenting cells. *Proc Natl Acad Sci U S A.* 1995;92:8078-8082.
159. Colonna M, Tinchieri G, Liu YJ. Plasmacytoid dendritic cells in immunity. *Nat Immunol.* 2004;5:1219-1226.
160. McKenna K, Beignon AS, Bhardwaj N. Plasmacytoid dendritic cells: linking innate and adaptive immunity. *J Virol.* 2005;79:17-27.
161. Banchereau J, Palucka AK. Dendritic cells as therapeutic vaccines against cancer. *Nat Rev Immunol.* 2005;5:296-306.
162. Siegal FP, Kadowaki N, Shodell M, et al. The nature of the principle type 1 interferon-producing cells in human blood. *Science.* 1999;284:1835-1837.
163. Iwasaki A, Medzhitov R. Toll-like receptor control of the adaptive immune responses. *Nat Immunol.* 2004;5:987-995. 7.
164. Coccia EM, Severa E, Giancomini D, et al. Viral infection and Toll-like receptor agonists induce a differential expression of type I and lambda interferons in human plasmacytoid and monocyte-derived dendritic cells. *Eur J Immunol.* 2004;34: 796-805.
165. Banchereau J, Paczesny S, Blanco P, et al. Dendritic cells: controllers of the immune system and a new promise for immunotherapy. *Ann N Y Acad Sci.* 2003;987:180-187.

166. Hartgers FC, Figdor CG, Adema GJ. Towards a molecular understanding of dendritic cell immunobiology. *Immunol Today*. 2000;21:542-545
167. Krug A, Towarowski S, Bristch S, et al. Toll-like receptor expression reveals CpG DNA as a unique microbial stimulus for plasmacytoid dendritic cells which synergizes with CD40 ligand to induce high amounts of IL-12. *Eur J Immunol*. 2001;31:3026-3037.
168. Chehimi J, Starr SE, Kawashima H, et al. Dendritic cells and IFN- γ -producing cells are two functionally distinct non-B, non-monocytic HLA-DR cell subsets in human peripheral blood. *Immunology*. 1989;68:488-490.
169. O'Doherty U, Peng M, Gezelter S, et al. Human blood contains two subsets of dendritic cells, one immunologically mature and the other immature. *Immunology*. 1994;82:487-493.
170. Grouard G, Risoan MC, Filgueira L, et al. The enigmatic plasmacytoid T cells develop into dendritic cells with interleukin (IL)-3 and CD40-ligand. *J Exp Med*. 1997;185:1101-1111.
171. Fiebiger E, Meraner P, Weber E, et al. Cytokines regulate proteolysis in major histocompatibility complex class II-dependent antigen presentation by dendritic cells. *J Exp Med*. 2001;193:881-892.
172. Ueda Y, Haigihara M, Okamoto A, et al. Frequencies of dendritic cells (myeloid DC and plasmacytoid DC) and their ratio reduced in pregnant women: comparison with umbilical cord blood and normal healthy adults. *Hum Immunol*. 2003; 64:1144-1151.
173. Kadowaki N, Antoneko S, Lau JYN, Liu YJ. Natural interferon- γ -producing cells link innate and adaptive immunity. *J Exp Med*. 2000;192:219-226.
174. Fitzgerald-Bocarsly P, Feldman PM, Mendelsohn M, Curl S, Lopez C. Human mononuclear cells which produce interferon- α during NK[HSV-FS] assays are HLA-DR positive cells distinct from cytolytic natural killer effectors. *J Leukoc Biol*. 1988;43:323-334.
175. Martin P, Del Hoyo GM, Anjuere F, et al. Characterization of a new subpopulation of mouse CD8 B220 dendritic cells endowed with type 1 interferon production capacity and tolerogenic potential. *Blood*. 2002;100:383-390.
176. Bilsborough J, Viney JL. Getting to the guts of immune regulation. *Immunology*. 2002;106:139-143.
177. Sallusto F, Lanzavecchia A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. *J Exp Med*. 1994;179:1109-1118.
178. Romani N, Reider D, Heuer M, et al. Generation of mature dendritic cells from human blood. An improved method with special regard to clinical applicability. *J Immunol Methods*. 1996;196:137-151.
179. Heiser A, Dahm P, Yancey DR, et al. Human dendritic cells transfected with RNA encoding prostate-specific antigen stimulate prostate-specific CTL responses in vitro. *J Immunol*. 2000;164:5508-5514.
180. Caux C, Dezutter-Dambuyant C, Schmidt D, Banchereau J. GM-CSF and TNF- α cooperate in the generation of dendritic Langerhans cells. *Nature*. 1992;360:258-261.
181. Caux C, Massacrier C, Dezutter-Dambuyant C, et al. Human dendritic Langerhans cells generated in vitro from CD34 progenitors can prime naive CD4 T cells and process soluble antigen. *J Immunol*. 1995;155:5427-5435.
182. Banchereau J, Palucka AK, Dhodapkar M, et al. Immune and clinical responses in patients with metastatic melanoma to CD34 progenitor-derived dendritic cell vaccine. *Cancer Res*. 2001;61:6451-6458.

183. Mackensen A, Herbst B, Chen JL, et al. Phase I study in melanoma patients of a vaccine with peptide-pulsed dendritic cells generated *in vitro* from CD34 hematopoietic progenitor cells. *Int J Cancer*. 2000;86:385-392.
184. Di Nicola M, Carlo-Stella C, Mortarini R, et al. Boosting T cell-mediated immunity to tyrosinase by vaccinia virus-transduced, CD34-derived dendritic cell vaccination: a phase I trial in metastatic melanoma. *Clin Cancer Res*. 2004;10:5381-5390.
185. Peters JH, Xu H, Ruppert J, et al. Signals required for differentiating dendritic cells from human monocytes in vitro. *Adv Exp Med Biol*. 1993;329:275-280.
186. Mohamadzadeh M, Berard F, Essert G, et al. Interleukin 15 skews monocyte differentiation into dendritic cells with features of Langerhans cells. *J Exp Med*. 2001;194:1013-1020.
187. Paquette RL, Hsu NC, Kiertscher SM, et al. Interferon- and granulocyte-macrophage colony-stimulating factor differentiated peripheral blood monocytes into potent antigen-presenting cells. *J Leukoc Biol*. 1998;64:358-367.
188. Butterfield LH, Ribas A, Dissette VB, et al. Determinant spreading associated with clinical response in dendritic cell-based immunotherapy for malignant melanoma. *Clin Cancer Res*. 2003;9:998-1008.
189. Ueda Y, Itoh T, Nukaya I, et al. Dendritic cell-based immunotherapy of cancer with carcinoembryonic antigen-derived, HLA-A24-restricted CTL epitope: clinical outcomes of 18 patients with metastatic gastrointestinal or lung adenocarcinomas. *Int J Oncol*. 2004;24:909-917.
190. Barrou B, Benoit G, Ouldkaci M, et al. Vaccination of prostatectomized prostate cancer patients in biochemical relapse, with autologous dendritic cells pulsed with recombinant human PSA. *Cancer Immunol Immunother*. 2004;53:453-460.
191. Hsu FJ, Benike C, Fagnoni F, et al. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. *Nat Med*. 1996;2:52-58.
192. Timmerman JM, Czerwinski DK, Davis TA, et al. Idiotypic pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients. *Blood*. 2002;99:1517-1526.
193. Reichardt VL, Milazzo C, Brugger W, et al. Idiotypic vaccination of multiple myeloma patients using monocyte-derived dendritic cells. *Haematologica*. 2003;88:1139-1149.
194. Heiser A, Coleman D, Dannull J, et al. Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors. *J Clin Invest*. 2002;109:409-417.
195. Su Z, Dannull J, Yang BK, et al. Telomerase mRNA-transfected dendritic cells stimulate antigen-specific CD8 and CD4 T cell responses in patients with metastatic prostate cancer. *J Immunol*. 2005;174:3798-3807.
196. Tucker MJ, Bretscher PA. T cells cooperating in the induction of delayed-type hypersensitivity act via the linked recognition of antigenic determinants. *J Exp Med*. 1982;155:1037-1049.
197. Bretscher PA. A cascade of T-T interactions, mediated by the linked recognition of antigen, in the induction of T cells able to help delayed-type hypersensitivity responses. *J Immunol*. 1986;137:3726-3733.

198. Mitchison NA, O'Malley C. Three-cell-type clusters of T cells with antigen-presenting cells best explain the epitope linkage and noncognate requirements of the *in vivo* cytolytic response. *Eur J Immunol*. 1987;17:1579-1583.
199. Shirai M, Pendleton CD, Ahlers J, et al. Helper-cytotoxic T lymphocyte (CTL) determinant linkage required for priming of anti-HIV CD8 CTL in vivo with peptide vaccine constructs. *J Immunol*. 1994;152:549-556.
200. Schuler-Thurner B, Schultz ES, Berger TG, et al. Rapid induction of tumor-specific type 1 T helper cells in metastatic melanoma patients by vaccination with mature, cryopreserved, peptide-loaded monocyte-derived dendritic cells. *J Exp Med*. 2002;195:1279-1288.
201. Smithers M, O'Connell K, MacFadyen S, et al. Clinical response after intradermal immature dendritic cell vaccination in metastatic melanoma is associated with immune response to particulate antigen. *Cancer Immunol Immunother*. 2003;52:41-52.
202. Svane IM, Pedersen AE, Johnsen HE, et al. Vaccination with p53-peptide-pulsed dendritic cells, of patients with advanced breast cancer: report from phase I study. *Cancer Immunol Immunother*. 2004;53:633-641.
203. Liu KJ, Wang CC, Chen LT, et al. Generation of carcino-embryonic antigen (CEA)-specific T-cell responses in HLA-A*0201 and HLA-A*2402 late-stage colorectal cancer patients after vaccination with dendritic cells loaded with CEA peptides. *Clin Cancer Res*. 2004;10:2645-2651.
204. Geiger JD, Hutchinson RJ, Hohenkirk LF, et al. Vaccination of pediatric solid tumor patients with tumor lysate-pulsed dendritic cells can expand specific T cells and mediate tumor regression. *Cancer Res*. 2001;61:8513-8519.
205. Chang AE, Redman BG, Whitfield JR, et al. A phase I trial of tumor lysate-pulsed dendritic cells in the treatment of advanced cancer. *Clin Cancer Res*. 2002;8:1021-1032.
206. Hernando JJ, Park TW, Kubler K, et al. Vaccination with autologous tumor antigen-pulsed dendritic cells in advanced gynaecological malignancies: clinical and immunological evaluation of a phase I trial. *Cancer Immunol Immunother*. 2002; 51:45-52.
207. Oosterwijk-Wakka JC, Tiemessen DM, Bleumer I, et al. Vaccination of patients with metastatic renal cell carcinoma with autologous dendritic cells pulsed with autologous tumor antigens in combination with interleukin-2: a phase I study. *J Immunother*. 2002;25:500-508.
208. Iwashita Y, Tahara K, Goto S, et al. A phase I study of autologous dendritic cell-based immunotherapy for patients with unresectable primary liver cancer. *Cancer Immunol Immunother*. 2003;52:155-161.
209. Yamanaka R, Abe T, Yajima N, et al. Vaccination of recurrent glioma patients with tumor lysate-pulsed dendritic cells elicits immune responses: results of a clinical phase I/II trial. *Br J Cancer*. 2003;89:1172-1179.
210. Stift A, Friedl P, Dubsky T, et al. Dendritic cell-based vaccination in solid cancer. *J Clin Oncol*. 2003;21:135-142.
211. Stift A, Sachet M, Yagubian R, et al. Dendritic cell vaccination in medullary thyroid carcinoma. *Clin Cancer Res*. 2004;10: 2944-2953.
212. Yu JS, Liu G, Ying H, et al. Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma. *Cancer Res*. 2004;64:4973-4979.

213. Pandha HS, John RJ, Hutchinson J, et al. Dendritic cell immunotherapy for urological cancers using cryopreserved allogeneic tumor lysate-pulsed cells: a phase I/II study. *BJU Int*. 2004;94:412-418.
214. Vilella R, Benitez D, Mila J, et al. Pilot study of treatment of biochemotherapy-refractory stage IV melanoma patients with autologous dendritic cells pulsed with a heterologous mela-noma cell line lysate. *Cancer Immunol Immunother*. 2004;53: 651-658.
215. Caruso DA, Orme LM, Neale AM, et al. Results of a phase 1 study utilizing monocyte-derived dendritic cells pulsed with tumor RNA in children and young adults with brain cancer. *Neurooncology*. 2004;6:236-246.
216. Caruso DA, Orme LM, Amor GM, et al. Results of a phase I study utilizing monocyte-derived dendritic cells pulsed with tumor RNA in children with stage 4 neuroblastoma. *Cancer*. 2005;103:1280-1291.
217. O'Rourke MGE, Johnson M, Lanagan C, et al. Durable complete clinical responses in a phase I/II trial using an autologous melanoma cell/dendritic cell vaccine. *Cancer Immunol Immunother*. 2003;52:387-395.
218. Yannelli JR, Sturgill J, Foody T, Hirschowitz E. The large scale generation of dendritic cells for the immunization of patients with non-small cell lung cancer (NSCLC). *Lung Cancer*. 2005;47:337-350.
219. Janetzki S, Palla D, Rosenhauer V, et al. Immunization of cancer patients with autologous cancer-derived heat shock protein gp96 preparations: a pilot study. *Int J Cancer*. 2000; 88:232-238.
220. Avigan D, Vasir B, Gong J, et al. Fusion cell vaccination of patients with metastatic breast and renal cancer induces immunological and clinical responses. *Clin Cancer Res*. 2004;10: 4966-4708.
221. Ossenkoppele GJ, Stam AGM, Westers TM, et al. Vaccination of chronic myeloid leukemia patients with autologous *in vitro* cultured leukemic dendritic cells. *Leukemia*. 2003;17: 1424-1426.
222. Choudhury A, Gajewski JL, Liang JC, et al. Use of leukemic dendritic cells for the generation of antileukemic cellular cytotoxicity against Philadelphia chromosome-positive chronic myelogenous leukemia. *Blood*. 1997;89:1133-1142.
223. Westers TM, Stam AG, Scheper RJ, et al. Rapid generation of antigen-presenting cells from leukemic blasts in acute myeloid leukemia. *Cancer Immunol Immunother*. 2003;52:17-27.
224. Houtenbos I, Westers TM, Stam AG, et al. Serum-free generation of antigen presenting cells from acute myeloid leukemic blasts for active specific immunisation. *Cancer Immunol Immunother*. 2003;52:455-462.
225. Wolkers MC, Brouwenstijn N, Bakker AH, Toebes M, Schumacher TNM. Antigen bias in T-cell cross-priming. *Science*. 2004;304:1314-1317.
226. Zinkernagel RM. On cross-priming of MHC class I-specific CTL: rule or exception? *Eur J Immunol*. 2002;32:2385-2392.
227. Ochsenbein AF, Siervo S, Odermatt B, et al. Roles of tumor localization, second signals and cross priming in cytotoxic
228. Steinman RM. Decisions about dendritic cells: past, present, and future. *Annu Rev Immunol* 2012; 30:1–22. | Article | PubMed | ISI | CAS |
229. Liu K, Nussenzweig MC. Origin and development of dendritic cells. *Immunol Rev* 2010; 234:45–54. | Article | PubMed | ISI | CAS |

230. Lee J, Breton G, Oliveira TY, *et al.* Restricted dendritic cell and monocyte progenitors in human cord blood and bone marrow. *J Exp Med* 2015; 212:385–399. | Article | PubMed | CAS |
231. Breton G, Lee J, Zhou YJ, *et al.* Circulating precursors of human CD1c⁺ and CD141⁺ dendritic cells. *J Exp Med* 2015; 212:401–413. | Article | PubMed | CAS |
232. Schlitzer A, Sivakamasundari V, Chen J, *et al.* Identification of cDC1- and cDC2-committed DC progenitors reveals early lineage priming at the common DC progenitor stage in the bone marrow. *Nat Immunol* 2015; 16:718–728. | Article | PubMed | CAS |
233. Breton G, Lee J, Liu K, Nussenzweig MC. Defining human dendritic cell progenitors by multiparametric flow cytometry. *Nat Protoc* 2015; 10:1407–1422. | Article |
234. Merad M, Sathe P, Helft J, Miller J, Mortha A. The dendritic cell lineage: ontogeny and function of dendritic cells and their subsets in the steady state and the inflamed setting. *Annu Rev Immunol* 2013; 31:563–604. | Article | PubMed | ISI | CAS |
235. Collin M, McGovern N, Haniffa M. Human dendritic cell subsets. *Immunology* 2013; 140:22–30. | Article | PubMed | ISI | CAS |
236. Haniffa M, Shin A, Bigley V, *et al.* Human tissues contain CD141^{hi} cross-presenting dendritic cells with functional homology to mouse CD103⁺ nonlymphoid dendritic cells. *Immunity* 2012; 37:60–73. | Article | PubMed | ISI | CAS |
237. Murphy TL, Grajales-Reyes GE, Wu X, *et al.* Transcriptional control of dendritic cell development. *Annu Rev Immunol* 2016; 34:93–119. | Article | CAS |
238. Meixlsperger S, Leung CS, Ramer PC, *et al.* CD141⁺ dendritic cells produce prominent amounts of IFN- α after dsRNA recognition and can be targeted via DEC-205 in humanized mice. *Blood* 2013; 121:5034–5044. | Article | PubMed | ISI | CAS |
239. Zhang S, Kodys K, Li K, Szabo G. Human type 2 myeloid dendritic cells produce interferon- λ and amplify interferon- α in response to hepatitis C virus infection. *Gastroenterology* 2013; 144:414–425.e7. | Article | PubMed | ISI | CAS |
240. Huysamen C, Willment JA, Dennehy KM, Brown GD. CLEC9A is a novel activation C-type lectin-like receptor expressed on BDCA3⁺ dendritic cells and a subset of monocytes. *J Biol Chem* 2008; 283:16693–16701. | Article | PubMed | CAS |
241. Sancho D, Joffre OP, Keller AM, *et al.* Identification of a dendritic cell receptor that couples sensing of necrosis to immunity. *Nature* 2009; 458:899–903. | Article | PubMed | ISI | CAS |
242. Cohn L, Chatterjee B, Esselborn F, *et al.* Antigen delivery to early endosomes eliminates the superiority of human blood BDCA3⁺ dendritic cells at cross presentation. *J Exp Med* 2013; 210:1049–1063. | Article | PubMed | ISI | CAS |
243. McKenna K, Beignon AS, Bhardwaj N. Plasmacytoid dendritic cells: linking innate and adaptive immunity. *J Virol* 2005; 79:17–27. | Article | PubMed | ISI | CAS |
244. Tel J, Schreiber G, Sittig SP, *et al.* Human plasmacytoid dendritic cells efficiently cross-present exogenous Ags to CD8⁺ T cells despite lower Ag uptake than myeloid dendritic cell subsets. *Blood* 2013; 121:459–467. | Article | PubMed | CAS |
245. Lui G, Manches O, Angel J, Molens JP, Chaperot L, Plumas J. Plasmacytoid dendritic cells capture and cross-present viral antigens from influenza-virus exposed cells. *PLoS One* 2009; 4:e7111. | Article |
246. O'Brien M, Manches O, Wilen C, *et al.* CD4 receptor is a key determinant of divergent HIV-1 sensing by plasmacytoid dendritic cells. *PLoS Pathog* 2016; 12:e1005553. | Article |

247. Salio M, Cella M, Vermi W, *et al.* Plasmacytoid dendritic cells prime IFN-gamma-secreting melanoma-specific CD8 lymphocytes and are found in primary melanoma lesions. *Eur J Immunol* 2003; 33:1052–1062. | Article | PubMed | ISI | CAS |
248. Hartmann E, Wollenberg B, Rothenfusser S, *et al.* Identification and functional analysis of tumor-infiltrating plasmacytoid dendritic cells in head and neck cancer. *Cancer Res* 2003; 63:6478–6487. | PubMed | ISI | CAS |
249. Gerlini G, Urso C, Mariotti G, *et al.* Plasmacytoid dendritic cells represent a major dendritic cell subset in sentinel lymph nodes of melanoma patients and accumulate in metastatic nodes. *Clin Immunol* 2007; 125:184–193. | Article | PubMed | CAS |
250. Battaglia A, Buzzonetti A, Baranello C, *et al.* Metastatic tumour cells favour the generation of a tolerogenic milieu in tumour draining lymph node in patients with early cervical cancer. *Cancer Immunol Immunother* 2009; 58:1363–1373. | Article |
251. Sharma MD, Baban B, Chandler P, *et al.* Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes directly activate mature Tregs via indoleamine 2,3-dioxygenase. *J Clin Invest* 2007; 117:2570–2582. | Article | PubMed | ISI | CAS |
252. Munn DH, Sharma MD, Hou D, *et al.* Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes. *J Clin Invest* 2004; 114:280–290. | Article | PubMed | ISI | CAS |
253. Segura E, Amigorena S. Inflammatory dendritic cells in mice and humans. *Trends Immunol* 2013; 34:440–445. | Article | PubMed | ISI | CAS |
254. McGovern N, Schlitzer A, Gunawan M, *et al.* Human dermal CD14(+) cells are a transient population of monocyte-derived macrophages. *Immunity* 2014; 41:465–477. | Article | PubMed | ISI | CAS |
255. Jaensson E, Uronen-Hansson H, Pabst O, *et al.* Small intestinal CD103⁺ dendritic cells display unique functional properties that are conserved between mice and humans. *J Exp Med* 2008; 205:2139–2149. | Article | PubMed | ISI | CAS |
256. Agace WW, Persson EK. How vitamin A metabolizing dendritic cells are generated in the gut mucosa. *Trends Immunol* 2012; 33:42–48. | Article | PubMed | ISI | CAS |
257. Reis e Sousa C. Dendritic cells in a mature age. *Nat Rev Immunol* 2006; 6:476–483. | Article | PubMed | ISI | CAS |
258. Jego G, Pascual V, Palucka AK, Banchereau J. Dendritic cells control B cell growth and differentiation. *Curr Dir Autoimmun* 2005; 8:124–139. | PubMed | CAS |
259. Munz C, Dao T, Ferlazzo G, de Cos MA, Goodman K, Young JW. Mature myeloid dendritic cell subsets have distinct roles for activation and viability of circulating human natural killer cells. *Blood* 2005; 105:266–273. | Article | PubMed |
260. Fujii S, Shimizu K, Kronenberg M, Steinman RM. Prolonged IFN-gamma-producing NKT response induced with α -galactosylceramide-loaded DCs. *Nat Immunol* 2002; 3:867–874. | Article | PubMed | ISI | CAS |
261. Akira S, Takeda K. Toll-like receptor signalling. *Nat Rev Immunol* 2004; 4:499–511. | Article | PubMed | ISI | CAS |
262. Kato H, Takeuchi O, Sato S, *et al.* Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses. *Nature* 2006; 441:101–105. | Article | PubMed | ISI | CAS |
263. Pedra JH, Cassel SL, Sutterwala FS. Sensing pathogens and danger signals by the inflammasome. *Curr Opin Immunol* 2009; 21:10–16. | Article | PubMed | ISI | CAS |
264. Skoberne M, Beignon AS, Bhardwaj N. Danger signals: a time and space continuum. *Trends Mol Med* 2004; 10:251–257. | Article | PubMed | ISI | CAS |

265. Gallo PM, Gallucci S. The dendritic cell response to classic, emerging, and homeostatic danger signals. Implications for autoimmunity. *Front Immunol* 2013; 4:138. | Article | PubMed | CAS |
266. Blum JS, Wearsch PA, Cresswell P. Pathways of antigen processing. *Annu Rev Immunol* 2013; 31:443–473. | Article | PubMed | ISI | CAS |
267. Segura E, Amigorena S. Cross-presentation in mouse and human dendritic cells. *Adv Immunol* 2015; 127:1–31. | PubMed |
268. Nair-Gupta P, Baccarini A, Tung N, *et al.* TLR signals induce phagosomal MHC-I delivery from the endosomal recycling compartment to allow cross-presentation. *Cell* 2014; 158:506–521. | Article | PubMed | ISI | CAS |
269. Banchereau J, Briere F, Caux C, *et al.* Immunobiology of dendritic cells. *Annu Rev Immunol* 2000; 18:767–811. | Article | PubMed | ISI | CAS |
270. Guermonprez P, Valladeau J, Zitvogel L, Thery C, Amigorena S. Antigen presentation and T cell stimulation by dendritic cells. *Annu Rev Immunol* 2002; 20:621–667. | Article | PubMed | ISI | CAS |
271. Joffre OP, Segura E, Savina A, Amigorena S. Cross-presentation by dendritic cells. *Nat Rev Immunol* 2012; 12:557–569. | Article | PubMed | ISI | CAS |
272. Brentville VA, Metheringham RL, Gunn B, *et al.* Citrullinated vimentin presented on MHC-II in tumor cells is a target for CD4⁺ T-cell-mediated antitumor immunity. *Cancer Res* 2016; 76:548–560. | Article |
273. Cobbold M, De La Pena H, Norris A, *et al.* MHC class I-associated phosphopeptides are the targets of memory-like immunity in leukemia. *Sci Transl Med* 2013; 5:203ra125. | Article | PubMed | CAS |
274. Geijtenbeek TB, Gringhuis SI. Signalling through C-type lectin receptors: shaping immune responses. *Nat Rev Immunol* 2009; 9:465–479. | Article | PubMed | ISI | CAS |
275. Benvenuti F. The dendritic cell synapse: a life dedicated to T cell activation. *Front Immunol* 2016; 7:70. | Article |
276. Penna G, Vulcano M, Sozzani S, Adorini L. Differential migration behavior and chemokine production by myeloid and plasmacytoid dendritic cells. *Hum Immunol* 2002; 63:1164–1171. | Article | PubMed | ISI | CAS |
277. Roberts EW, Broz ML, Binnewies M, *et al.* Critical role for CD103⁺/CD141⁺ dendritic cells bearing CCR7 for tumor antigen trafficking and priming of T cell immunity in melanoma. *Cancer Cell* 2016; 30:324–336. | Article | PubMed | CAS |
278. Gerner MY, Torabi-Parizi P, Germain RN. Strategically localized dendritic cells promote rapid T cell responses to lymph-borne particulate antigens. *Immunity* 2015; 42:172–185. | Article | PubMed | ISI | CAS |
279. Colino J, Shen Y, Snapper CM. Dendritic cells pulsed with intact *Streptococcus pneumoniae* elicit both protein- and polysaccharide-specific immunoglobulin isotype responses *in vivo* through distinct mechanisms. *J Exp Med* 2002; 195:1–13. | Article | PubMed | CAS |
280. Yamazaki C, Miyamoto R, Hoshino K, *et al.* Conservation of a chemokine system, XCR1 and its ligand, XCL1, between human and mice. *Biochem Biophys Res Commun* 2010; 397:756–761. | Article | PubMed | CAS |
281. Fox JC, Nakayama T, Tyler RC, Sander TL, Yoshie O, Volkman BF. Structural and agonist properties of XCL2, the other member of the C-chemokine subfamily. *Cytokine* 2015; 71:302–311. | Article |

282. Skoberne M, Beignon AS, Larsson M, Bhardwaj N. Apoptotic cells at the crossroads of tolerance and immunity. *Curr Top Microbiol Immunol* 2005; 289:259–292. | PubMed | CAS |
283. Cools N, Ponsaerts P, Van Tendeloo VF, Berneman ZN. Balancing between immunity and tolerance: an interplay between dendritic cells, regulatory T cells, and effector T cells. *J Leukoc Biol* 2007; 82:1365–1374. | Article | PubMed | ISI | CAS |
284. Mellor AL, Munn DH. IDO expression by dendritic cells: tolerance and tryptophan catabolism. *Nat Rev Immunol* 2004; 4:762–774. | Article | PubMed | ISI | CAS |
285. Munn DH, Mellor AL. IDO and tolerance to tumors. *Trends Mol Med* 2004; 10:15–18. | Article | PubMed | ISI | CAS |
286. Levings MK, Gregori S, Tresoldi E, Cazzaniga S, Bonini C, Roncarolo MG. Differentiation of Tr1 cells by immature dendritic cells requires IL-10 but not CD25⁺CD4⁺ T cells. *Blood* 2005; 105:1162–1169. | Article | PubMed | ISI | CAS |
287. Jonuleit H, Schmitt E, Schuler G, Knop J, Enk AH. Induction of interleukin 10-producing, nonproliferating CD4(+) T cells with regulatory properties by repetitive stimulation with allogeneic immature human dendritic cells. *J Exp Med* 2000; 192:1213–1222. | Article | PubMed | ISI | CAS |
288. Woo EY, Chu CS, Goletz TJ, *et al.* Regulatory CD4⁺CD25⁺ T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. *Cancer Res* 2001; 61:4766–4772. | PubMed | ISI | CAS |
289. Liyanage UK, Moore TT, Joo HG, *et al.* Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. *J Immunol* 2002; 169:2756–2761. | Article | PubMed | ISI | CAS |
290. Tang Q, Bluestone JA. The Foxp3⁺ regulatory T cell: a jack of all trades, master of regulation. *Nat Immunol* 2008; 9:239–244. | Article | PubMed | ISI | CAS |
291. Idoyaga J, Fiorese C, Zbytniuk L, *et al.* Specialized role of migratory dendritic cells in peripheral tolerance induction. *J Clin Invest* 2013; 123:844–854. | PubMed | ISI | CAS |
292. Skoberne M, Somersan S, Almodovar W, *et al.* The apoptotic-cell receptor CR3, but not $\alpha\beta 5$, is a regulator of human dendritic-cell immunostimulatory function. *Blood* 2006; 108:947–955. | Article | PubMed | ISI | CAS |
293. Frleta D, Ochoa CE, Kramer HB, *et al.* HIV-1 infection-induced apoptotic microparticles inhibit human DCs via CD44. *J Clin Invest* 2012; 122:4685–4697. | Article |
294. Kalialis LV, Drzewiecki KT, Klyver H. Spontaneous regression of metastases from melanoma: review of the literature. *Melanoma Res* 2009; 19:275–282. | Article | PubMed | ISI |
295. Wang RF, Rosenberg SA. Human tumor antigens for cancer vaccine development. *Immunol Rev* 1999; 170:85–100. | Article | PubMed | ISI | CAS |
296. Kim R, Emi M, Tanabe K. Cancer immunoediting from immune surveillance to immune escape. *Immunology* 2007; 121:1–14. | Article | PubMed | ISI | CAS |
297. Dunn GP, Old LJ, Schreiber RD. The three Es of cancer immunoediting. *Annu Rev Immunol* 2004; 22:329–360. | Article | PubMed | ISI | CAS |
298. Dhodapkar MV, Steinman RM, Sapp M, *et al.* Rapid generation of broad T-cell immunity in humans after a single injection of mature dendritic cells. *J Clin Invest* 1999; 104:173–180. | Article | PubMed | ISI | CAS |
299. Constantino J, Gomes C, Falcao A, Cruz MT, Neves BM. Antitumor dendritic cell-based vaccines: lessons from 20 years of clinical trials and future perspectives. *Transl Res* 2016; 168:74–95. | Article | CAS |

300. Lundberg K, Albrekt AS, Nelissen I, *et al.* Transcriptional profiling of human dendritic cell populations and models--unique profiles of *in vitro* dendritic cells and implications on functionality and applicability. *PLoS One* 2013; 8:e52875. | Article | PubMed |
301. Carpentier S, Vu Manh TP, Chelbi R, *et al.* Comparative genomics analysis of mononuclear phagocyte subsets confirms homology between lymphoid tissue-resident and dermal XCR1⁺ DCs in mouse and human and distinguishes them from Langerhans cells. *J Immunol Methods* 2016; 432:35–49. | Article |
302. Gandhi RT, O'Neill D, Bosch RJ, *et al.* A randomized therapeutic vaccine trial of canarypox-HIV-pulsed dendritic cells vs. canarypox-HIV alone in HIV-1-infected patients on antiretroviral therapy. *Vaccine* 2009; 27:6088–6094. | Article |
303. Palucka AK, Ueno H, Connolly J, *et al.* Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8⁺ T-cell immunity. *J Immunother* 2006; 29:545–557. | Article | PubMed | ISI | CAS |
304. Redman BG, Chang AE, Whitfield J, *et al.* Phase Ib trial assessing autologous, tumor-pulsed dendritic cells as a vaccine administered with or without IL-2 in patients with metastatic melanoma. *J Immunother* 2008; 31:591–598. | Article |
305. O'Neill DW, Bhardwaj N. Differentiation of peripheral blood monocytes into dendritic cells. *Curr Protoc Immunol* 2005; Chapter 22:Unit 22F.24.
306. O'Neill D, Bhardwaj N. Generation of autologous peptide- and protein-pulsed dendritic cells for patient-specific immunotherapy. *Methods Mol Med* 2005; 109:97–112.
307. Florcken A, Kopp J, van Lessen A, *et al.* Allogeneic partially HLA-matched dendritic cells pulsed with autologous tumor cell lysate as a vaccine in metastatic renal cell cancer: a clinical phase I/II study. *Hum Vaccin Immunother* 2013; 9:1217–1227. | Article | PubMed |
308. Kumar J, Kale V, Limaye L. Umbilical cord blood-derived CD11c(+) dendritic cells could serve as an alternative allogeneic source of dendritic cells for cancer immunotherapy. *Stem Cell Res Ther* 2015; 6:184. | Article |
309. Pinzon-Charry A, Maxwell T, Lopez JA. Dendritic cell dysfunction in cancer: a mechanism for immunosuppression. *Immunol Cell Biol* 2005; 83:451–461. | Article | PubMed | ISI | CAS |
310. Wells JW, Cowled CJ, Darling D, *et al.* Semi-allogeneic dendritic cells can induce antigen-specific T-cell activation, which is not enhanced by concurrent alloreactivity. *Cancer Immunol Immunother* 2007; 56:1861–1873. | Article | PubMed |
311. Fabre JW. The allogeneic response and tumor immunity. *Nat Med* 2001; 7:649–652. | Article | PubMed | ISI | CAS |
312. Ratzinger G, Baggers J, de Cos MA, *et al.* Mature human Langerhans cells derived from CD34⁺ hematopoietic progenitors stimulate greater cytolytic T lymphocyte activity in the absence of bioactive IL-12p70, by either single peptide presentation or cross-priming, than do dermal-interstitial or monocyte-derived dendritic cells. *J Immunol* 2004; 173:2780–2791. | Article | PubMed | ISI | CAS |
313. Romano E, Rossi M, Ratzinger G, *et al.* Peptide-loaded Langerhans cells, despite increased IL15 secretion and T-cell activation *in vitro*, elicit antitumor T-cell responses comparable to peptide-loaded monocyte-derived dendritic cells *in vivo*. *Clin Cancer Res* 2011; 17:1984–1997. | Article |
314. Yuan J, Latouche JB, Reagan JL, *et al.* Langerhans cells derived from genetically modified human CD34⁺ hemopoietic progenitors are more potent than peptide-pulsed Langerhans cells for inducing antigen-specific CD8⁺ cytolytic T lymphocyte responses. *J Immunol* 2005; 174:758–766. | Article |

315. Lee J, Breton G, Aljoufi A, *et al.* Clonal analysis of human dendritic cell progenitor using a stromal cell culture. *J Immunol Methods* 2015; 425:21–26. | Article |
316. Kantoff PW, Higano CS, Shore ND, *et al.* Sipuleucel-T immunotherapy for castration-resistant prostate cancer. *N Engl J Med* 2010; 363:411–422. | Article | PubMed | ISI | CAS |
317. Small EJ, Schellhammer PF, Higano CS, *et al.* Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. *J Clin Oncol* 2006; 24:3089–3094. | Article | PubMed | ISI | CAS |
318. Small EJ, Fratesi P, Reese DM, *et al.* Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells. *J Clin Oncol* 2000; 18:3894–3903. | PubMed | ISI | CAS |
319. Sheikh NA, Jones LA. CD54 is a surrogate marker of antigen presenting cell activation. *Cancer Immunol Immunother* 2008; 57:1381–1390. | Article | PubMed | CAS |
320. GuhaThakurta D, Sheikh NA, Fan LQ, *et al.* Humoral immune response against nontargeted tumor antigens after treatment with sipuleucel-T and its association with improved clinical outcome. *Clin Cancer Res* 2015; 21:3619–3630. | Article |
321. Sheikh NA, Petrylak D, Kantoff PW, *et al.* Sipuleucel-T immune parameters correlate with survival: an analysis of the randomized phase 3 clinical trials in men with castration-resistant prostate cancer. *Cancer Immunol Immunother* 2013; 62:137–147. | Article | PubMed | CAS |
322. Fong L, Carroll P, Weinberg V, *et al.* Activated lymphocyte recruitment into the tumor microenvironment following preoperative sipuleucel-T for localized prostate cancer. *J Natl Cancer Inst* 2014; 106.
323. Marroquin CE, Westwood JA, Lapointe R, *et al.* Mobilization of dendritic cell precursors in patients with cancer by flt3 ligand allows the generation of higher yields of cultured dendritic cells. *J Immunother* 2002; 25:278–288. | Article | PubMed | ISI |
324. Anandasabapathy N, Breton G, Hurley A, *et al.* Efficacy and safety of CDX-301, recombinant human Flt3L, at expanding dendritic cells and hematopoietic stem cells in healthy human volunteers. *Bone Marrow Transplant* 2015; 50:924–930. | Article | PubMed |
325. Chen W, Antonenko S, Sederstrom JM, *et al.* Thrombopoietin cooperates with FLT3-ligand in the generation of plasmacytoid dendritic cell precursors from human hematopoietic progenitors. *Blood* 2004; 103:2547–2553. | Article | PubMed | ISI | CAS |
326. Tel J, Aarntzen EH, Baba T, *et al.* Natural human plasmacytoid dendritic cells induce antigen-specific T-cell responses in melanoma patients. *Cancer Res* 2013; 73:1063–1075. | Article | PubMed | CAS |
327. Schreiber G, Bol KF, Westdorp H, *et al.* Effective clinical responses in metastatic melanoma patients after vaccination with primary myeloid dendritic cells. *Clin Cancer Res* 2016; 22:2155–2166. | Article |
328. Carreno BM, Magrini V, Becker-Hapak M, *et al.* A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells. *Science* 2015; 348:803–808. | Article | PubMed | CAS |
329. De Vries IJ, Krooshoop DJ, Scharenborg NM, *et al.* Effective migration of antigen-pulsed dendritic cells to lymph nodes in melanoma patients is determined by their maturation state. *Cancer Res* 2003; 63:12–17. | PubMed | ISI | CAS |

330. Dhodapkar MV, Steinman RM, Krasovsky J, Munz C, Bhardwaj N. Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells. *J Exp Med* 2001; 193:233–238. | Article | PubMed | ISI | CAS |
331. Dhodapkar MV, Steinman RM. Antigen-bearing immature dendritic cells induce peptide-specific CD8(+) regulatory T cells *in vivo* in humans. *Blood* 2002; 100:174–177. | Article | PubMed | ISI | CAS |
332. de Vries IJ, Lesterhuis WJ, Scharenborg NM, *et al.* Maturation of dendritic cells is a prerequisite for inducing immune responses in advanced melanoma patients. *Clin Cancer Res* 2003; 9:5091–5100. | PubMed | ISI | CAS |
333. Lee AW, Truong T, Bickham K, *et al.* A clinical grade cocktail of cytokines and PGE2 results in uniform maturation of human monocyte-derived dendritic cells: implications for immunotherapy. *Vaccine* 2002; 20 Suppl 4:A8–A22.
334. Jongmans W, Tiemessen DM, van Vlodrop IJ, Mulders PF, Oosterwijk E. Th1-polarizing capacity of clinical-grade dendritic cells is triggered by Ribomunyl but is compromised by PGE2: the importance of maturation cocktails. *J Immunother* 2005; 28:480–487. | Article | PubMed |
335. Krause P, Singer E, Darley PI, Klebensberger J, Groettrup M, Legler DF. Prostaglandin E2 is a key factor for monocyte-derived dendritic cell maturation: enhanced T cell stimulatory capacity despite IDO. *J Leukoc Biol* 2007; 82:1106–1114. | Article | PubMed | ISI |
336. Morelli AE, Thomson AW. Dendritic cells under the spell of prostaglandins. *Trends Immunol* 2003; 24:108–111. | Article | PubMed | ISI |
337. Scandella E, Men Y, Gillessen S, Forster R, Groettrup M. Prostaglandin E2 is a key factor for CCR7 surface expression and migration of monocyte-derived dendritic cells. *Blood* 2002; 100:1354–1361. | Article | PubMed | ISI | CAS |
338. Krause P, Bruckner M, Uermosi C, Singer E, Groettrup M, Legler DF. Prostaglandin E(2) enhances T-cell proliferation by inducing the costimulatory molecules OX40L, CD70, and 4-1BBL on dendritic cells. *Blood* 2009; 113:2451–2460. | Article | PubMed | ISI |
339. Ma DY, Clark EA. The role of CD40 and CD154/CD40L in dendritic cells. *Semin Immunol* 2009; 21:265–272. | Article | PubMed | ISI | CAS |
340. Carreno BM, Becker-Hapak M, Huang A, *et al.* IL-12p70-producing patient DC vaccine elicits Tc1-polarized immunity. *J Clin Invest* 2013; 123:3383–3394. | Article | PubMed | ISI | CAS |
341. Schnare M, Barton GM, Holt AC, Takeda K, Akira S, Medzhitov R. Toll-like receptors control activation of adaptive immune responses. *Nat Immunol* 2001; 2:947–950. | Article | PubMed | ISI | CAS |
342. Napolitani G, Rinaldi A, Bertoni F, Sallusto F, Lanzavecchia A. selected toll-like receptor agonist combinations synergistically trigger a T helper type 1-polarizing program in dendritic cells. *Nat Immunol* 2005; 6:769–776. | Article | PubMed | ISI | CAS |
343. Boullart AC, Aarntzen EH, Verdijk P, *et al.* Maturation of monocyte-derived dendritic cells with toll-like receptor 3 and 7/8 ligands combined with prostaglandin E2 results in high interleukin-12 production and cell migration. *Cancer Immunol Immunother* 2008; 57:1589–1597. | Article |
344. Mailliard RB, Wankowicz-Kalinska A, Cai Q, *et al.* α -type-1 polarized dendritic cells: a novel immunization tool with optimized CTL-inducing activity. *Cancer Res* 2004; 64:5934–5937. | Article | PubMed | ISI | CAS |

345. Lee JJ, Foon KA, Mailliard RB, Muthuswamy R, Kalinski P. Type 1-polarized dendritic cells loaded with autologous tumor are a potent immunogen against chronic lymphocytic leukemia. *J Leukoc Biol* 2008; 84:319–325. | Article | PubMed | ISI |
346. Okada H, Kalinski P, Ueda R, *et al.* Induction of CD8⁺ T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with α -type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in patients with recurrent malignant glioma. *J Clin Oncol* 2011; 29:330–336. | Article | PubMed | ISI | CAS |
347. Chiang CL, Kandalaft LE, Tanyi J, *et al.* A dendritic cell vaccine pulsed with autologous hypochlorous acid-oxidized ovarian cancer lysate primes effective broad antitumor immunity: from bench to bedside. *Clin Cancer Res* 2013; 19:4801–4815. | Article |
348. Kolanowski ST, Sritharan L, Lissenberg-Thunnissen SN, Van Schijndel GM, Van Ham SM, ten Brinke A. Comparison of media and serum supplementation for generation of monophosphoryl lipid A/interferon-gamma-matured type I dendritic cells for immunotherapy. *Cytotherapy* 2014; 16:826–834. | Article |
349. Pantel A, Cheong C, Dandamudi D, *et al.* A new synthetic TLR4 agonist, GLA, allows dendritic cells targeted with antigen to elicit Th1 T-cell immunity *in vivo*. *Eur J Immunol* 2012; 42:101–109. | Article | PubMed | CAS |
350. Schreibelt G, Benitez-Ribas D, Schuurhuis D, *et al.* Commonly used prophylactic vaccines as an alternative for synthetically produced TLR ligands to mature monocyte-derived dendritic cells. *Blood* 2010; 116:564–574. | Article |
351. Bol KF, Aarntzen EH, Pots JM, *et al.* Prophylactic vaccines are potent activators of monocyte-derived dendritic cells and drive effective anti-tumor responses in melanoma patients at the cost of toxicity. *Cancer Immunol Immunother* 2016; 65:327–339. | Article |
352. Langenkamp A, Messi M, Lanzavecchia A, Sallusto F. Kinetics of dendritic cell activation: impact on priming of TH1, TH2 and nonpolarized T cells. *Nat Immunol* 2000; 1:311–316. | Article | PubMed | ISI | CAS |
353. Dohnal AM, Graffi S, Witt V, *et al.* Comparative evaluation of techniques for the manufacturing of dendritic cell-based cancer vaccines. *J Cell Mol Med* 2009; 13:125–135. | Article | PubMed |
354. Bijker MS, van den Eeden SJ, Franken KL, Melief CJ, van der Burg SH, Offringa R. Superior induction of anti-tumor CTL immunity by extended peptide vaccines involves prolonged, DC-focused antigen presentation. *Eur J Immunol* 2008; 38:1033–1042. | Article | PubMed | ISI | CAS |
355. Linnemann C, van Buuren MM, Bies L, *et al.* High-throughput epitope discovery reveals frequent recognition of neo-antigens by CD4⁺ T cells in human melanoma. *Nat Med* 2015; 21:81–85. | Article | PubMed | ISI | CAS |
356. Kenter GG, Welters MJ, Valentijn AR, *et al.* Phase I immunotherapeutic trial with long peptides spanning the E6 and E7 sequences of high-risk human papillomavirus 16 in end-stage cervical cancer patients shows low toxicity and robust immunogenicity. *Clin Cancer Res* 2008; 14:169–177. | Article | PubMed | ISI | CAS |
357. Welters MJ, Kenter GG, Piersma SJ, *et al.* Induction of tumor-specific CD4⁺ and CD8⁺ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine. *Clin Cancer Res* 2008; 14:178–187. | Article | PubMed | ISI | CAS |

358. Kenter GG, Welters MJ, Valentijn AR, *et al.* Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. *N Engl J Med* 2009; 361:1838–1847. | Article | PubMed | ISI | CAS |
359. de Vos van Steenwijk PJ, Ramwadhoebe TH, Lowik MJ, *et al.* A placebo-controlled randomized HPV16 synthetic long-peptide vaccination study in women with high-grade cervical squamous intraepithelial lesions. *Cancer Immunol Immunother* 2012; 61:1485–1492. | Article | PubMed | CAS |
360. Leffers N, Lambeck AJ, Gooden MJ, *et al.* Immunization with a P53 synthetic long peptide vaccine induces P53-specific immune responses in ovarian cancer patients, a phase II trial. *Int J Cancer* 2009; 125:2104–2113. | Article | PubMed | ISI | CAS |
361. Sabbatini P, Tsuji T, Ferran L, *et al.* Phase I trial of overlapping long peptides from a tumor self-antigen and poly-ICLC shows rapid induction of integrated immune response in ovarian cancer patients. *Clin Cancer Res* 2012; 18:6497–6508. | Article | PubMed | ISI | CAS |
362. Zeestraten EC, Speetjens FM, Welters MJ, *et al.* Addition of interferon- α to the p53-SLP(R) vaccine results in increased production of interferon-gamma in vaccinated colorectal cancer patients: a phase I/II clinical trial. *Int J Cancer* 2013; 132:1581–1591. | Article | PubMed | CAS |
363. Speetjens FM, Kuppen PJ, Welters MJ, *et al.* Induction of p53-specific immunity by a p53 synthetic long peptide vaccine in patients treated for metastatic colorectal cancer. *Clin Cancer Res* 2009; 15:1086–1095. | Article | PubMed | ISI | CAS |
364. Rosario M, Borthwick N, Stewart-Jones GB, *et al.* Prime-boost regimens with adjuvanted synthetic long peptides elicit T cells and antibodies to conserved regions of HIV-1 in macaques. *AIDS* 2012; 26:275–284. | Article | PubMed |
365. Barrou B, Benoit G, Ouldakaci M, *et al.* Vaccination of prostatectomized prostate cancer patients in biochemical relapse, with autologous dendritic cells pulsed with recombinant human PSA. *Cancer Immunol Immunother* 2004; 53:453–460. | Article | PubMed | ISI |
366. Salcedo M, Bercovici N, Taylor R, *et al.* Vaccination of melanoma patients using dendritic cells loaded with an allogeneic tumor cell lysate. *Cancer Immunol Immunother* 2006; 55:819–829. | Article | PubMed | ISI | CAS |
367. Mahdian R, Kokhaei P, Najari HM, Derkow K, Choudhury A, Mellstedt H. Dendritic cells, pulsed with lysate of allogeneic tumor cells, are capable of stimulating MHC-restricted antigen-specific antitumor T cells. *Med Oncol* 2006; 23:273–282. | Article |
368. Schnurr M, Galambos P, Scholz C, *et al.* Tumor cell lysate-pulsed human dendritic cells induce a T-cell response against pancreatic carcinoma cells: an *in vitro* model for the assessment of tumor vaccines. *Cancer Res* 2001; 61:6445–6450. | PubMed | ISI | CAS |
369. Thumann P, Moc I, Humrich J, *et al.* Antigen loading of dendritic cells with whole tumor cell preparations. *J Immunol Methods* 2003; 277:1–16. | Article | PubMed | ISI |
370. Schnurr M, Chen Q, Shin A, *et al.* Tumor antigen processing and presentation depend critically on dendritic cell type and the mode of antigen delivery. *Blood* 2005; 105:2465–2472. | Article | PubMed | ISI | CAS |
371. Vandenberk L, Belmans J, Van Woensel M, Riva M, Van Gool SW. Exploiting the immunogenic potential of cancer cells for improved dendritic cell vaccines. *Front Immunol* 2015; 6:663.

372. Somersan S, Larsson M, Fonteneau JF, Basu S, Srivastava P, Bhardwaj N. Primary tumor tissue lysates are enriched in heat shock proteins and induce the maturation of human dendritic cells. *J Immunol* 2001; 167:4844–4852. | Article | PubMed | ISI | CAS |
373. Hatfield P, Merrick AE, West E, *et al.* Optimization of dendritic cell loading with tumor cell lysates for cancer immunotherapy. *J Immunother* 2008; 31:620–632. | Article | PubMed | ISI |
374. Garg AD, Vandenberk L, Koks C, *et al.* Dendritic cell vaccines based on immunogenic cell death elicit danger signals and T cell-driven rejection of high-grade glioma. *Sci Transl Med* 2016; 8:328ra327. | Article |
375. Rosenblatt J, Vasir B, Uhl L, *et al.* Vaccination with dendritic cell/tumor fusion cells results in cellular and humoral antitumor immune responses in patients with multiple myeloma. *Blood* 2011; 117:393–402. | Article | PubMed | ISI | CAS |
376. Jenne L, Schuler G, Steinkasserer A. Viral vectors for dendritic cell-based immunotherapy. *Trends Immunol* 2001; 22:102–107. | Article | PubMed | ISI | CAS |
377. Brockstedt DG, Dubensky TW. Promises and challenges for the development of *Listeria monocytogenes*-based immunotherapies. *Expert Rev Vaccines* 2008; 7:1069–1084. | Article | PubMed |
378. Bellone S, El-Sahwi K, Cocco E, *et al.* Human papillomavirus type 16 (HPV-16) virus-like particle L1-specific CD8⁺ cytotoxic T lymphocytes (CTLs) are equally effective as E7-specific CD8⁺ CTLs in killing autologous HPV-16-positive tumor cells in cervical cancer patients: implications for L1 dendritic cell-based therapeutic vaccines. *J Virol* 2009; 83:6779–6789. | Article |
379. Carrasco J, Van Pel A, Neyns B, *et al.* Vaccination of a melanoma patient with mature dendritic cells pulsed with MAGE-3 peptides triggers the activity of nonvaccine anti-tumor cells. *J Immunol* 2008; 180:3585–3593. | Article | PubMed | CAS |
380. Butterfield LH, Comin-Anduix B, Vujanovic L, *et al.* Adenovirus MART-1-engineered autologous dendritic cell vaccine for metastatic melanoma. *J Immunother* 2008; 31:294–309. | Article | PubMed | ISI |
381. Veron P, Allo V, Riviere C, Bernard J, Douar AM, Masurier C. Major subsets of human dendritic cells are efficiently transduced by self-complementary adeno-associated virus vectors 1 and 2. *J Virol* 2007; 81:5385–5394. | Article | PubMed | ISI | CAS |
382. Skoberne M, Yewdall A, Bahjat KS, *et al.* KBMA *Listeria monocytogenes* is an effective vector for DC-mediated induction of antitumor immunity. *J Clin Invest* 2008; 118:3990–4001. | Article | PubMed | ISI |
383. Oldham RA, Berinstein EM, Medin JA. Lentiviral vectors in cancer immunotherapy. *Immunotherapy* 2015; 7:271–284. | Article | PubMed |
384. Breckpot K, Heirman C, De Greef C, van der Bruggen P, Thielemans K. Identification of new antigenic peptide presented by HLA-Cw7 and encoded by several MAGE genes using dendritic cells transduced with lentiviruses. *J Immunol* 2004; 172:2232–2237. | Article | PubMed | ISI | CAS |
385. He Y, Zhang J, Mi Z, Robbins P, Falo LD Jr. Immunization with lentiviral vector-transduced dendritic cells induces strong and long-lasting T cell responses and therapeutic immunity. *J Immunol* 2005; 174:3808–3817. | Article | PubMed | ISI | CAS |
386. Dullaers M, Van Meirvenne S, Heirman C, *et al.* Induction of effective therapeutic antitumor immunity by direct *in vivo* administration of lentiviral vectors. *Gene Ther* 2006; 13:630–640. | Article | PubMed | ISI | CAS |

387. Schroers R, Sinha I, Segall H, *et al.* Transduction of human PBMC-derived dendritic cells and macrophages by an HIV-1-based lentiviral vector system. *Mol Ther* 2000; 1:171–179. | Article | PubMed | ISI | CAS |
388. Dyllal J, Latouche JB, Schnell S, Sadelain M. Lentivirus-transduced human monocyte-derived dendritic cells efficiently stimulate antigen-specific cytotoxic T lymphocytes. *Blood* 2001; 97:114–121. | Article | PubMed | ISI | CAS |
389. Lizee G, Gonzales MI, Topalian SL. Lentivirus vector-mediated expression of tumor-associated epitopes by human antigen presenting cells. *Hum Gene Ther* 2004; 15:393–404. | Article | PubMed | ISI | CAS |
390. Bobadilla S, Sunseri N, Landau NR. Efficient transduction of myeloid cells by an HIV-1-derived lentiviral vector that packages the Vpx accessory protein. *Gene Ther* 2013; 20:514–520. | Article | PubMed | ISI | CAS |
391. Varela-Rohena A, Carpenito C, Perez EE, *et al.* Genetic engineering of T cells for adoptive immunotherapy. *Immunol Res* 2008; 42:166–181. | Article | PubMed |
392. Sundarasetty BS, Chan L, Darling D, *et al.* Lentivirus-induced 'Smart' dendritic cells: pharmacodynamics and GMP-compliant production for immunotherapy against TRP2-positive melanoma. *Gene Ther* 2015; 22:707–720. | Article |
393. Woller N, Knocke S, Mundt B, *et al.* Virus-induced tumor inflammation facilitates effective DC cancer immunotherapy in a Treg-dependent manner in mice. *J Clin Invest* 2011; 121:2570–2582. | Article | PubMed |
394. Nair SK, Morse M, Boczkowski D, *et al.* Induction of tumor-specific cytotoxic T lymphocytes in cancer patients by autologous tumor RNA-transfected dendritic cells. *Ann Surg* 2002; 235:540–549. | Article | PubMed | ISI |
395. Muller MR, Tsakou G, Grunebach F, Schmidt SM, Brossart P. Induction of chronic lymphocytic leukemia (CLL)-specific CD4- and CD8-mediated T-cell responses using RNA-transfected dendritic cells. *Blood* 2004; 103:1763–1769. | Article | PubMed | ISI | CAS |
396. Nencioni A, Muller MR, Grunebach F, *et al.* Dendritic cells transfected with tumor RNA for the induction of antitumor CTL in colorectal cancer. *Cancer Gene Ther* 2003; 10:209–214. | Article | PubMed | ISI | CAS |
397. Milazzo C, Reichardt VL, Muller MR, Grunebach F, Brossart P. Induction of myeloma-specific cytotoxic T cells using dendritic cells transfected with tumor-derived RNA. *Blood* 2003; 101:977–982. | Article | PubMed | ISI | CAS |
398. Gilboa E, Vieweg J. Cancer immunotherapy with mRNA-transfected dendritic cells. *Immunol Rev* 2004; 199:251–263. | Article | PubMed | ISI | CAS |
399. Heiser A, Maurice MA, Yancey DR, Coleman DM, Dahm P, Vieweg J. Human dendritic cells transfected with renal tumor RNA stimulate polyclonal T-cell responses against antigens expressed by primary and metastatic tumors. *Cancer Res* 2001; 61:3388–3393. | PubMed | ISI | CAS |
400. Strobel I, Berchtold S, Gotze A, Schulze U, Schuler G, Steinkasserer A. Human dendritic cells transfected with either RNA or DNA encoding influenza matrix protein M1 differ in their ability to stimulate cytotoxic T lymphocytes. *Gene Ther* 2000; 7:2028–2035. | Article | PubMed | ISI | CAS |
401. Koido S, Kashiwaba M, Chen D, Gendler S, Kufe D, Gong J. Induction of antitumor immunity by vaccination of dendritic cells transfected with MUC1 RNA. *J Immunol* 2000; 165:5713–5719. | Article | PubMed | ISI | CAS |

402. Heiser A, Coleman D, Dannull J, *et al.* Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors. *J Clin Invest* 2002; 109:409–417. | Article | PubMed | ISI | CAS |
403. Routy JP, Boulassel MR, Yassine-Diab B, *et al.* Immunologic activity and safety of autologous HIV RNA-electroporated dendritic cells in HIV-1 infected patients receiving antiretroviral therapy. *Clin Immunol* 2010; 134:140–147. | Article | PubMed | ISI | CAS |
404. Amin A, Dudek AZ, Logan TF, *et al.* Survival with AGS-003, an autologous dendritic cell-based immunotherapy, in combination with sunitinib in unfavorable risk patients with advanced renal cell carcinoma (RCC): phase 2 study results. *J Immunother Cancer* 2015; 3:14. | Article | PubMed |
405. Obeid J, Hu Y, Slingluff CL Jr. Vaccines, adjuvants, and dendritic cell activators--current status and future challenges. *Semin Oncol* 2015; 42:549–561. | Article |
406. Schumacher TN, Schreiber RD. Neoantigens in cancer immunotherapy. *Science* 2015; 348:69–74. | Article | PubMed | CAS |
407. Brown SD, Warren RL, Gibb EA, *et al.* Neo-antigens predicted by tumor genome meta-analysis correlate with increased patient survival. *Genome Res* 2014; 24:743–750. | Article | PubMed | ISI | CAS |
408. Rooney MS, Shukla SA, Wu CJ, Getz G, Hacohen N. Molecular and genetic properties of tumors associated with local immune cytolytic activity. *Cell* 2015; 160:48–61. | Article | PubMed | ISI | CAS |
409. Rizvi NA, Hellmann MD, Snyder A, *et al.* Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. *Science* 2015; 348:124–128. | Article | PubMed | ISI | CAS |
410. Snyder A, Makarov V, Merghoub T, *et al.* Genetic basis for clinical response to CTLA-4 blockade in melanoma. *N Engl J Med* 2014; 371:2189–2199. | Article | PubMed | ISI | CAS |
411. Van Allen EM, Miao D, Schilling B, *et al.* Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. *Science* 2015; 350:207–211. | Article | PubMed | CAS |
412. Hugo W, Zaretsky JM, Sun L, *et al.* Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma. *Cell* 2016; 165:35–44. | Article | PubMed | CAS |
413. Carreno BM, Magrini V, Becker-Hapak M, *et al.* Cancer immunotherapy. A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells. *Science* 2015; 348:803–808. | Article | PubMed | CAS |
414. Verdijk P, Aarntzen EH, Lesterhuis WJ, *et al.* Limited amounts of dendritic cells migrate into the T-cell area of lymph nodes but have high immune activating potential in melanoma patients. *Clin Cancer Res* 2009; 15:2531–2540. | Article | PubMed | ISI | CAS |
415. Fujiwara S, Wada H, Miyata H, *et al.* Clinical trial of the intratumoral administration of labeled DC combined with systemic chemotherapy for esophageal cancer. *J Immunother* 2012; 35:513–521. | Article | PubMed |
416. Lesterhuis WJ, de Vries IJ, Schreibelt G, *et al.* Route of administration modulates the induction of dendritic cell vaccine-induced antigen-specific T cells in advanced melanoma patients. *Clin Cancer Res* 2011; 17:5725–5735. | Article | PubMed | CAS |
417. Aarntzen EH, Srinivas M, Bonetto F, *et al.* Targeting of 111in-labeled dendritic cell human vaccines improved by reducing number of cells. *Clin Cancer Res* 2013; 19:1525–1533. | Article |

418. Mitchell DA, Batich KA, Gunn MD, *et al.* Tetanus toxoid and CCL3 improve dendritic cell vaccines in mice and glioblastoma patients. *Nature* 2015; 519:366–369. | Article | PubMed | ISI | CAS |
419. Headley MB, Bins A, Nip A, *et al.* Visualization of immediate immune responses to pioneer metastatic cells in the lung. *Nature* 2016; 531:513–517. | Article | PubMed | CAS |
420. Yewdall AW, Drutman SB, Jinwala F, Bahjat KS, Bhardwaj N. CD8⁺ T cell priming by dendritic cell vaccines requires antigen transfer to endogenous antigen presenting cells. *PLoS One* 2010; 5:e11144. | Article | PubMed | CAS |
421. Spranger S, Bao R, Gajewski TF. Melanoma-intrinsic β -catenin signalling prevents anti-tumour immunity. *Nature* 2015; 523:231–235. | Article | PubMed | CAS |
422. Salmon H, Idoyaga J, Rahman A, *et al.* Expansion and activation of CD103⁺ dendritic cell progenitors at the tumor site enhances tumor responses to therapeutic PD-L1 and BRAF inhibition. *Immunity* 2016; 44:924–938. | Article | PubMed | CAS |
423. Shortman K, Lahoud MH, Caminschi I. Improving vaccines by targeting antigens to dendritic cells. *Exp Mol Med* 2009; 41:61–66. | Article | PubMed | ISI | CAS |
424. Tacken PJ, Torensma R, Figdor CG. Targeting antigens to dendritic cells *in vivo*. *Immunobiology* 2006; 211:599–608. | Article | PubMed | ISI | CAS |
425. Jinushi M, Hodi FS, Dranoff G. Enhancing the clinical activity of granulocyte-macrophage colony-stimulating factor-secreting tumor cell vaccines. *Immunol Rev* 2008; 222:287–298. | Article | PubMed | CAS |
426. Jinushi M, Tahara H. Cytokine gene-mediated immunotherapy: current status and future perspectives. *Cancer Sci* 2009; 100:1389–1396. | Article | PubMed | ISI |
427. Lutz ER, Wu AA, Bigelow E, *et al.* Immunotherapy converts nonimmunogenic pancreatic tumors into immunogenic foci of immune regulation. *Cancer Immunol Res* 2014; 2:616–631. | Article | PubMed | ISI | CAS |
428. Le DT, Wang-Gillam A, Picozzi V, *et al.* Safety and survival with GVAX pancreas prime and *Listeria monocytogenes*-expressing mesothelin (CRS-207) boost vaccines for metastatic pancreatic cancer. *J Clin Oncol* 2015; 33:1325–1333. | Article | PubMed | CAS |
429. Filipazzi P, Valenti R, Huber V, *et al.* Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor-based antitumor vaccine. *J Clin Oncol* 2007; 25:2546–2553. | Article | PubMed | ISI | CAS |
430. Sica A, Bronte V. Altered macrophage differentiation and immune dysfunction in tumor development. *J Clin Invest* 2007; 117:1155–1166. | Article | PubMed | ISI | CAS |
431. Nowak AK, Robinson BW, Lake RA. Synergy between chemotherapy and immunotherapy in the treatment of established murine solid tumors. *Cancer Res* 2003; 63:4490–4496. | PubMed | ISI | CAS |
432. Beatty GL, Torigian DA, Chiorean EG, *et al.* A phase I study of an agonist CD40 monoclonal antibody (CP-870,893) in combination with gemcitabine in patients with advanced pancreatic ductal adenocarcinoma. *Clin Cancer Res* 2013; 19:6286–6295. | Article | PubMed | ISI | CAS |
433. Bajor DL, Xu X, Torigian DA, *et al.* Immune activation and a 9-year ongoing complete remission following CD40 antibody therapy and metastasectomy in a patient with metastatic melanoma. *Cancer Immunol Res* 2014; 2:1051–1058. | Article | PubMed |
434. Winograd R, Byrne KT, Evans RA, *et al.* Induction of T-cell immunity overcomes complete resistance to PD-1 and CTLA-4 blockade and improves survival in pancreatic carcinoma. *Cancer Immunol Res* 2015; 3:399–411. | Article | PubMed | CAS |

435. van Kooyk Y. C-type lectins on dendritic cells: key modulators for the induction of immune responses. *Biochem Soc Trans* 2008; 36:1478–1481. | Article | PubMed | CAS |
436. Idoyaga J, Lubkin A, Fiorese C, *et al.* Comparable T helper 1 (Th1) and CD8 T-cell immunity by targeting HIV gag p24 to CD8 dendritic cells within antibodies to Langerin, DEC205, and Clec9A. *Proc Natl Acad Sci USA* 2011; 108:2384–2389. | Article | PubMed |
437. Kato Y, Zaid A, Davey GM, *et al.* Targeting antigen to Clec9A primes follicular Th cell memory responses capable of robust recall. *J Immunol* 2015; 195:1006–1014. | Article | PubMed | CAS |
438. Lahoud MH, Ahmet F, Kitsoulis S, *et al.* Targeting antigen to mouse dendritic cells via Clec9A induces potent CD4 T cell responses biased toward a follicular helper phenotype. *J Immunol* 2011; 187:842–850. | Article | PubMed | ISI | CAS |
439. Li J, Ahmet F, Sullivan LC, *et al.* Antibodies targeting Clec9A promote strong humoral immunity without adjuvant in mice and non-human primates. *Eur J Immunol* 2015; 45:854–864. | Article | PubMed |
440. Tullett KM, Leal Rojas IM, Minoda Y, *et al.* Targeting CLEC9A delivers antigen to human CD141⁺ DC for CD4⁺ and CD8⁺T cell recognition. *JCI Insight* 2016; 1:e87102. | Article |
441. Wang B, Zaidi N, He LZ, *et al.* Targeting of the non-mutated tumor antigen HER2/neu to mature dendritic cells induces an integrated immune response that protects against breast cancer in mice. *Breast Cancer Res* 2012; 14:R39. | Article | PubMed | CAS |
442. Cheong C, Choi JH, Vitale L, *et al.* Improved cellular and humoral immune responses *in vivo* following targeting of HIV Gag to dendritic cells within human anti-human DEC205 monoclonal antibody. *Blood* 2010; 116:3828–3838. | Article | PubMed | ISI |
443. Tacke PJ, de Vries IJ, Gijzen K, *et al.* Effective induction of naive and recall T-cell responses by targeting antigen to human dendritic cells via a humanized anti-DC-SIGN antibody. *Blood* 2005; 106:1278–1285. | Article | PubMed | ISI | CAS |
444. Ramakrishna V, Treml JF, Vitale L, *et al.* Mannose receptor targeting of tumor antigen pmel17 to human dendritic cells directs anti-melanoma T cell responses via multiple HLA molecules. *J Immunol* 2004; 172:2845–2852. | Article | PubMed | ISI | CAS |
445. Trumpfheller C, Longhi MP, Caskey M, *et al.* Dendritic cell-targeted protein vaccines: a novel approach to induce T-cell immunity. *J Int Med* 2012; 271:183–192. | Article |
446. Hartung E, Becker M, Bachem A, *et al.* Induction of potent CD8 T cell cytotoxicity by specific targeting of antigen to cross-presenting dendritic cells *in vivo* via murine or human XCR1. *J Immunol* 2015; 194:1069–1079. | Article | PubMed |
447. Terhorst D, Fossum E, Baranska A, *et al.* Laser-assisted intradermal delivery of adjuvant-free vaccines targeting XCR1⁺ dendritic cells induces potent antitumoral responses. *J Immunol* 2015; 194:5895–5902. | Article |
448. Fossum E, Grodeland G, Terhorst D, *et al.* Vaccine molecules targeting Xcr1 on cross-presenting DCs induce protective CD8⁺ T-cell responses against influenza virus. *Eur J Immunol* 2015; 45:624–635. | Article | CAS |
449. Kranz LM, Diken M, Haas H, *et al.* Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy. *Nature* 2016; 534:396–401. | Article | PubMed | CAS |
450. Saeterdal I, Bjorheim J, Lislud K, *et al.* Frameshift-mutation-derived peptides as tumor-specific antigens in inherited and spontaneous colorectal cancer. *Proc Natl Acad Sci USA* 2001; 98:13255–13260. | Article | PubMed | CAS |

451. Sharma A, Koldovsky U, Xu S, *et al.* HER-2 pulsed dendritic cell vaccine can eliminate HER-2 expression and impact ductal carcinoma *in situ*. *Cancer* 2012; 118:4354–4362. | Article | PubMed |
452. Draube A, Klein-Gonzalez N, Mattheus S, *et al.* Dendritic cell based tumor vaccination in prostate and renal cell cancer: a systematic review and meta-analysis. *PLoS One* 2011; 6:e18801. | Article | PubMed | CAS |
453. Bennaceur K, Chapman J, Brikci-Nigassa L, Sanhadji K, Touraine JL, Portoukalian J. Dendritic cells dysfunction in tumour environment. *Cancer Lett* 2008; 272:186–196. | Article | PubMed | CAS |
454. Aptsiauri N, Cabrera T, Mendez R, Garcia-Lora A, Ruiz-Cabello F, Garrido F. Role of altered expression of HLA class I molecules in cancer progression. *Adv Exp Med Biol* 2007; 601:123–131. |
455. Bronte V, Mocellin S. Suppressive influences in the immune response to cancer. *J Immunother* 2009; 32:1–11. | Article | PubMed | ISI |
456. Chang CC, Ogino T, Mullins DW, *et al.* Defective human leukocyte antigen class I-associated antigen presentation caused by a novel beta2-microglobulin loss-of-function in melanoma cells. *J Biol Chem* 2006; 281:18763–18773. | Article | PubMed | CAS |
457. Wilgenhof S, Corthals J, Heirman C, *et al.* Phase II study of autologous monocyte-derived mRNA electroporated dendritic cells (TriMixDC-MEL) plus ipilimumab in patients with pretreated advanced melanoma. *J Clin Oncol* 2016; 34:1330–1338. | Article |
458. Pol J, Kroemer G, Galluzzi L. First oncolytic virus approved for melanoma immunotherapy. *Oncoimmunology* 2016; 5:e1115641. | Article |
459. SE, Chiocca EA. Oncolytic virus-mediated immunotherapy: a combinatorial approach for cancer treatment. *J Clin Oncol* 2015; 33:2812–2814. | Article |
460. Salazar AM, Erlich RB, Mark A, Bhardwaj N, Herberman RB. Therapeutic *in situ* autovaccination against solid cancers with intratumoral poly-ICLC: case report, hypothesis, and clinical trial. *Cancer Immunol Res* 2014; 2:720–724. | Article |
461. Brody JD, Ai WZ, Czerwinski DK, *et al.* *In situ* vaccination with a TLR9 agonist induces systemic lymphoma regression: a phase I/II study. *J Clin Oncol* 2010; 28:4324–4332. | Article | PubMed | ISI |
462. de Vries CR, Kaufman HL, Lattime EC. Oncolytic viruses: focusing on the tumor microenvironment. *Cancer Gene Ther* 2015; 22:169–171. | Article |
463. Corrales L, Glickman LH, McWhirter SM, *et al.* Direct activation of STING in the tumor microenvironment leads to potent and systemic tumor regression and immunity. *Cell Rep* 2015; 11:1018–1030. | Article | PubMed | CAS |
464. Senju S, Hirata S, Motomura Y, *et al.* Pluripotent stem cells as source of dendritic cells for immune therapy. *Int J Hematol* 2010; 91:392–400. | Article | PubMed | ISI |
465. Li Y, Liu M, Yang ST. Dendritic cells derived from pluripotent stem cells: potential of large scale production. *World J Stem Cells* 2014; 6:1–10. | Article |
466. Zeng J, Wu C, Wang S. Antigenically modified human pluripotent stem cells generate antigen-presenting dendritic cells. *Sci Rep* 2015; 5:15262. | Article |
467. White MK, Khalili K. CRISPR/Cas9 and cancer targets: future possibilities and present challenges. *Oncotarget* 2016; 7:12305–12317. | PubMed |